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Equine grass sickness (EGS) is a frequently fatal multi-system neurodegenerative 
disease, characterised by chromatolysis of the central, autonomic, enteric and somatic 
neurons of grazing equids. 
An accurate, minimally invasive, ante-mortem, diagnostic test for EGS is currently 
lacking. While histological examination of haematoxylin and eosin stained rectal 
biopsies for chromatolytic neurons is insensitive as a diagnostic test for EGS, it was 
hypothesised that the diagnostic accuracy could be improved by immunolabelling for 
β-amyloid precursor protein (β-APP) which has increased expression in cranial 
cervical ganglia neuronal perikarya in EGS. The objective of the first part of the study 
was to develop a grading scheme for assessing the distribution and intensity of β-APP 
immunoreactivity within individual rectal submucosal neurons and subsequently to 
determine the diagnostic value of the distribution of different grades of neurons for 
EGS diagnosis. A retrospective case-control diagnostic accuracy study was performed. 
β-amyloid precursor protein immunoreactivity was increased in neuronal perikarya in 
biopsies of rectum from 21 EGS horses compared with those from 23 control horses. 
A weighted immunoreactivity grade exceeding 1.1 was 100% specific and sensitive 
for EGS, and the presence of at least one neuron with diffuse labelling of the entire 
cytoplasm (grade 3) was 95% sensitive and 100% specific for EGS. In conclusion, 
histological assessment of β-APP immunolabelled rectal biopsies is more accurate 
than conventional histological examination for EGS diagnosis. Further validation is 
required before this technique can be advocated for clinical decision making. 
While acute and sub-acute EGS are invariably fatal, some chronic grass sickness 
(CGS) cases survive. Currently there are no objective criteria for predicting the 
outcome of CGS cases. The objective of the second part of the study was to determine 
whether the rate and/ or magnitude of bodyweight change of CGS cases during 
hospitalisation can provide an objective predictor of survival to discharge from 
hospital. A single centre retrospective observational study was performed by analysing 
the case records of all horses admitted for management of CGS to The Dick Vet Equine 
Hospital, University of Edinburgh between 1998 and 2013. The study sample 
comprised 213 horses, with 53.5% survivors (S) and 46.5% non-survivors (NS). 
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Compared with NS, S had significantly lower median maximum bodyweight loss as a 
percentage of first weight (S 5.9%, interquartile range 1.8-13.5; NS 12.7%, 6.4-17.3). 
Throughout all time periods analysed (0-7, 7-14, 14-21, 21-28, 0-14, 0-21 and 0-28 
days from first weight recorded) S had significantly lower median bodyweight loss 
than NS, but no specific time period was more predictive of survival. Highest 
percentages of total bodyweight loss for individual horses were comparable for S 
(36%) and NS (37%). Survival prediction curves reporting percentage survival rates 
for all time periods analysed provided data to aid prediction of CGS survival. In 
conclusion NS had greater bodyweight loss than S. Rapidity and magnitude of 
bodyweight loss were equally predictive of outcome. Percentage survival prediction 
curves provide objective data to aid discussion of prognosis, but greater predictive 


















Equine grass sickness (EGS) is a disease of grazing horses which causes degeneration 
of nerves throughout the central and involuntary nervous systems, and particularly of 
the gastrointestinal tract. The majority of cases are fatal.  
There is currently no accurate, minimally invasive, test to diagnose EGS in live 
animals. Standard microscopic examination of degenerating nerve cells in rectal 
biopsies is not a sensitive test for EGS diagnosis. It was hypothesised that the accuracy 
of using rectal biopsies in the diagnosis of EGS could be improved by labelling β-
amyloid precursor protein (β-APP), a protein which accumulates within degenerating 
nerve cells. The aim of the first part of the study was to develop a grading scheme to 
assess the degree of β-APP labelling and subsequently determine if the distribution of 
different grades of labelling within nerve cells in rectal biopsies aids EGS diagnosis. 
β-APP labelling accumulated in nerve cells in rectal biopsies from 21 EGS horses 
compared with those from 23 control horses. An average grade of labelling allowed 
differentiation of all of the control and EGS horse samples. The presence of at least 
one nerve cell with generalised labelling allowed differentiation of 95% of the 
samples. In conclusion, labelling rectal biopsies with β-APP is more accurate than 
standard microscopic examination for diagnosing EGS. This technique needs to be 
tested in a greater number of cases before it can be used in real clinical cases.  
A proportion of chronic grass sickness (CGS) cases, a milder form of the disease, can 
survive. However there are no objective criteria to help predict whether cases are likely 
to survive or require euthanasia on humane grounds. The aim of the second part of the 
study was to determine if the rate and magnitude of bodyweight change of CGS horses 
can predict which horses are likely to survive to discharge from the hospital. Horses 
admitted for management of CGS to The Dick Vet Equine Hospital, University of 
Edinburgh, between 1998 and 2013, were considered for inclusion in the study. Two 
hundred and thirteen horses were included in the study with 53.5% survivors (S) and 
46.5% non-survivors (NS). On average NS lost a greater proportion of bodyweight 
than S, but this was not always the case for each individual horse. The highest 
percentage of bodyweight loss for individual horses were comparable for S (36%) and 
NS (37%), and consequently each case should be assessed on an individual case by 
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case basis. Curves predicting the likelihood of survival of CGS horses, based on the 
rate and magnitude of weight loss, were generated to provide data to help predict 
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AUC  area under the curve  
β-APP  β-amyloid precursor protein  
CCG  cranial cervical ganglia/ ganglion   
CGS  chronic grass sickness  
EGS  equine grass sickness   
GIT   gastrointestinal tract  
H&E  haematoxylin and eosin 
ICC   interstitial cells of Cajal  
IQR  interquartile range(s) 
LMN   lower motor neuron(s)  
ROC  receiver operating characteristic  
NS  non-survivor(s) 
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1 Chapter One: Literature review 
1.1   Introduction    
Equine grass sickness (EGS), or equine dysautonomia, is a frequently fatal multi-
system neurodegenerative disease, characterised by chromatolysis of the central, 
autonomic, enteric and somatic neurons of grazing equids. Disease severity is 
principally determined by the extent of neuronal degeneration in the submucosal and 
myenteric plexuses of the enteric nervous system, which, in the case of acute and 
subacute forms of the disease, is incompatible with life. Currently the only ante-
mortem diagnostic test for EGS with high sensitivity and specificity is assessment of 
ileal histopathology, which requires invasive sampling; a less invasive method would 
clearly be desirable. Whilst a proportion of horses with chronic grass sickness (CGS) 
will survive, there are currently no objective criteria to predict survival of these cases. 
This literature review will discuss the scientific literature on EGS with an emphasis on 
current diagnostic techniques, histopathology and prognosis of the disease.  
 
1.2   Clinical signs and disease sub-classification  
Equine grass sickness presents as one of three clinical forms; acute, subacute and 
chronic. These categories are traditionally classified in the veterinary literature 
according to duration of survival; 1-2, 2-7 and >7 days, respectively (Hudson and Pirie, 
2005, Lyle and Pirie, 2009, Pirie et al., 2014). However, this method of sub-
classification, which relates exclusively to duration of survival, is somewhat arbitrary, 
with inevitable overlap between the three forms due to interventional factors 
(supportive care and elective euthanasia) which may affect duration of survival (Pirie 
et al., 2014). The extent of neuronal damage is of a continuum scale and the sub-
classifications should also be thought of as such, with some overlap observed (Pirie, 
2002). The clinical sub-classifications should be based on the nature and progression 
of clinical signs (Pirie et al., 2014), both of which correlate with the extent of neuronal 
damage (Pogson et al., 1992, Doxey et al., 1992, Scholes et al., 1993b, Doxey et al., 
1995b).   
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Correctly sub-classifying EGS is important with regard to prognosis. Acute and 
subacute forms of the disease are considered to be invariably fatal and treatment is not 
recommended (Pirie et al., 2014). Some cases of CGS survive with appropriate nursing 
care (Milne et al., 1994, Doxey et al., 1995a, Doxey et al., 1998, Doxey et al., 1999).    
From a clinical perspective, the EGS disease phenotype principally reflects 
dysfunction of the parasympathetic neurons in the enteric nervous system, with the 
remainder of clinical signs attributable to the dysfunction of remaining autonomic and 
somatic neurons (Scholes et al., 1993b, Hahn, 2000, Hahn et al., 2001). All sub-
classifications of the disease may demonstrate signs of dullness, anorexia, oral, 
pharyngeal and oesophageal dysphagia, salivation, colic, reduced gastrointestinal 
motility, tachycardia, bilateral ptosis, patchy sweating and muscle fasciculations, 
predominantly of the triceps and quadriceps (Hudson and Pirie, 2005, Wylie and 
Proudman, 2009, Lyle and Pirie, 2009). The severity of these signs often correlates 
with the sub-classification of disease (Pirie et al., 2014), e.g. the magnitude of 
tachycardia and intestinal dysmotility is greater in acute than subacute and chronic 
forms of the disease.  
In addition to the above clinical signs, chronic cases are usually characterised by 
profound weight loss (McGorum and Kirk, 2001), with a characteristic ‘tucked up’ 
abdominal silhouette. The magnitude of weight loss appears greater than that which 
can solely be attributed to a lack of food intake and cachexia is suspected (McGorum 
and Kirk, 2001). Progressive generalised myasthenia occurs, as demonstrated by a 
base-narrow ‘elephant on a tub’ stance, leaning against walls, weight shifting between 
limbs and increased periods of recumbency (Lyle and Pirie, 2009, Pirie et al., 2014). 
In contrast to cases of neuroparalytic botulism, the muscle fasciculations observed 
whilst standing often persist during periods of recumbency and it is speculated that 
other factors, in addition to weakness, may contribute to the fasciculations (Pirie et al., 
2014). Rhinitis sicca is considered to be pathognomonic for the disease, and may cause 
nasal obstruction and respiratory noise in the chronic form of the disease (Prince et al., 
2003). Examination per rectum often reveals dry faecal pellets coated with inspissated 
mucus in all forms of the disease (Pirie et al., 2014). The main differential diagnoses 
for CGS include botulism, equine motor neuron disease, hypocalcaemia and other 
causes of dysphagia and weight loss (Lyle and Pirie, 2009).  
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The firm and corrugated secondary large colon and caecal impactions present in 
subacute and some acute cases differentiate this category from the chronic form and 
reflect the moderate ileus present (Lyle and Pirie, 2009). The predominant differential 
diagnosis for subacute EGS is a primary large colon impaction, an unusual finding in 
a grass kept horse, or impactions that occur as a secondary consequence of other 
primary conditions, such as large colon displacement.  
Acute EGS cases have marked acute gastrointestinal ileus with gastric and generalised 
small intestinal distension and subsequent high volume malodorous gastric reflux, 
which may spontaneously reflux via the nares (Pirie et al., 2014). The primary 
differential diagnosis for acute cases is a strangulating or non-strangulating small 
intestinal obstruction (Lyle and Pirie, 2009). Apart from a degree of 
haemoconcentration, cases of EGS have cardiovascular stability, despite being 
markedly tachycardic (typically 70-120 beats/ min). The relative absence of abdominal 
pain in acute EGS may aid differentiation from surgical colic cases.   
 
1.3 Epidemiology  
The first case of EGS was reported in Angus, Scotland, in 1909 (Greig, 1942). Equine 
grass sickness has since been reported throughout the UK and northern Europe, 
including France (Lhomme et al., 1996), Belgium (Christmann et al., 1999), the 
Netherlands (Leendertse, 1993), Germany, Switzerland (Eser et al., 2000), Denmark 
(Bendixen, 1946), Hungary (Schwarz et al., 2012), Austria (Wlaschitz and Url, 2004), 
Sweden (Obel, 1955) and the Czech Republic (Melkova et al., 2014). The first 
histopathologically confirmed case of EGS in southern Europe occurred in Cyprus 
(Protopapas et al., 2012). Confirmed cases have also been reported in the Falklands 
(Woods and Gilmour, 1991), Australia (Stewart, 1977), and a single case in a mule in 
the United States (Wright et al., 2010). A condition, clinically and pathologically, 
indistinguishable from EGS called ‘mal seco’ (dry sickness) is recognised in 
Argentina, the Falklands and Chile (Uzal et al., 1994, Uzal and Robles, 1993, Uzal et 
al., 1992, Araya et al., 2002). Further histopathological investigations are necessary to 
determine whether the disease called ‘tambora’ occurring in Columbia is the same 
disease (Oliver-Espinosa, 2008).  
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Equine grass sickness affects all equidae including donkeys (Wylie et al., 2011, Mellor 
et al., 2013), mules (Wright et al., 2010), zebras (Ashton et al., 1977) and Przewalski’s 
horses (Ashton et al., 1977, Girling et al., 2015). The most recent overall median 
incidence rates for EGS, on premises having at least one previous incident of EGS, is 
reported as 2% annually (Newton et al., 2004, Ireland et al., 2011). The incidence is 
highest in East Scotland (Wood et al., 1998, McCarthy et al., 2001, Wylie et al., 2011).  
Whilst the aetiological agent of EGS remains unknown, recent epidemiological 
investigations have identified multiple risk factors, suggesting a multifactorial 
aetiology is most likely.  
1.3.1 Horse related risk factors  
1.3.1.1 Age  
Whilst the disease has been diagnosed in horses from 12 days (McGorum et al., 2003) 
to 47 years of age (Wylie et al., 2011), younger horses have consistently been reported 
as being at greater risk of EGS. The largest case-control study examining signalment 
reported the highest incidence of EGS in two year olds (Wylie et al., 2014) whilst other 
studies consistently found younger mature horses (3 to 6 years) to be at greater risk 
(Doxey et al., 1991a, Wood et al., 1998, McCarthy et al., 2004, Wylie et al., 2011). It 
is speculated that the association of EGS with particular age categories may reflect 
different levels of protective passive and acquired immunity and/ or tolerance to the 
causal agent (Wood et al., 1998, McCarthy et al., 2004, Wylie et al., 2014).  
1.3.1.2 Breed 
Two studies found certain breeds to have a greater association with the disease 
following univariable analyses (Wood et al., 1998, McCarthy et al., 2004), however 
these associations were not significant after multivariable analyses. Native Scottish 
breeds compared to crossbreds were reported in a single study to be at increased risk 
in both uni- and multivariable analyses (Wylie et al., 2014). Other studies have 
reported breeds with an increased/ decreased chance of survival (Milne et al., 1994, 
Doxey et al., 1998), however these findings are inconsistent, with other studies failing 




Wylie et al. (2014) reported stallions to be associated with lower odds of developing 
EGS compared with mares, which contrasts with an earlier study (Wood et al., 1998) 
that reported females less likely to be affected. The majority of studies have found no 
gender predispositions to EGS (Doxey et al., 1991a, Wylie et al., 2011).  
1.3.1.4 Body condition   
Doxey et al. (1991a) found 95% of EGS cases to be in good/ fat bodily condition 
compared to 52% of the control population, however, the control data were collected 
at a different time of the year. More recently, Wood et al. (1998) reported that horses 
in good condition were not at any greater risk.      
1.3.1.5 Immunological status   
During investigations to determine if non-fatal exposure to the causative agent of EGS 
induces protection, Wood et al. (1998) reported that horses with a history of prior 
contact with an EGS case were associated with an approximately 10-fold reduced 
likelihood of disease. Furthermore, McCarthy et al. (2004) found that increasing serum 
antibody titres to Clostridium botulinum type C, C. botulinum C1 neurotoxin and C. 
novyi type A surface antigens were significantly associated with a decreased risk of 
EGS. 
1.3.2 Climate related risk factors  
1.3.2.1 Seasonal incidence  
Although EGS cases have been reported as occurring in every month of the year 
(Wylie et al., 2011), the disease has a clear seasonal occurrence. Consistent with the 
Veterinary Clinical Observation Unit (1970) grass sickness survey report for Scotland 
in which 40% of cases occurred in May, Doxey et al. (1991a) reported higher 
incidences between April and July, with a principal peak in May. A study over 10 
years (Wylie et al., 2011) reported 60.6% of cases occurred during April, May and 
June, with the fewest cases in January. Early studies have reported a second peak of 
EGS cases in autumn in Scotland (Doxey et al., 1991a), but this has not been 
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subsequently confirmed in nationwide surveillance reports (Wylie et al., 2011). It is 
likely that geographically localised trends in occurrence have been lost in the 
nationwide averages reported by Wylie et al. (2011).   
1.3.2.2 Weather patterns  
It has been reported that the majority of outbreaks occur during cooler, drier weather 
associated with irregular ground frosts (Doxey et al., 1991b). Wood et al. (1998) 
reported that 66% of cases were preceded by 2 weeks of predominantly dry weather.  
The largest case-control study of EGS to date confirmed a number of meteorological 
related risk factors associated with increased risk of EGS; lower average temperature 
(average difference 0.08-0.13oC), greater sunshine hours (average difference 0.01-0.05 
hours) and frost days (average difference 0.05-0.2 days) (Wylie et al., 2014). Whilst 
the magnitudes of the average differences were not large, some associations were 
consistent with previous reports (Doxey et al., 1991b, Wood et al., 1998). However, 
unlike the earlier reports that identified a short-term temporal association, Wylie et al. 
(2014) only identified statistically significant differences for data over longer time 
periods (e.g. average frost days was only statistically significant if 6 or more months 
were averaged).  
1.3.3 Premises related risk factors  
1.3.3.1 Type of establishment  
Whilst specifically analysing the type of equestrian establishment by the type of work 
undertaken, Doxey et al. (1991a) failed to identify a correlation between the type of 
work and incidence of EGS. In contrast, Newton et al. (2004) found an increased rate 
of EGS recurrence in stud farms and riding establishments in univariable but not 
multivariable analyses.    
1.3.3.2 Soil type 
Loam and sandy soils were associated with an increased risk of recurrence of EGS and 
chalk soils with decreased recurrence (Newton et al., 2004). It was speculated that as 
sand and loam soils may be more easily disturbed and turned over, soil inhabitants, 
such as earthworms and moles, are able to burrow freely, causing disruption and 
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increasing the rate of contamination of grass with soil borne microorganisms (Newton 
et al., 2004).  
1.3.3.3 Previous occurrence of equine grass sickness  
Animals on premises where EGS had previously occurred within the last two years 
were at increased risk of EGS (Wood et al., 1998). Wylie et al. (2011) found most 
cases reported from England and Wales occurred on premises that had not previously 
had a case of EGS, while in Scotland most cases were reported from premises that had 
a case of EGS previously.  
1.3.4 Management related risk factors  
1.3.4.1 Grazing 
As the name suggests, there is a strong association between the development of EGS 
and grazing (Wood et al., 1998). Both Doxey et al. (1991a) and Wood et al. (1998) 
identified a significantly higher incidence of EGS in horses grazing full time compared 
to part time. Whilst rare cases have been reported in horses entirely stable kept these 
were either not histologically confirmed (Forsyth, 1941, Wood et al., 1998) or had 
only been stabled for 1 week (Wood et al., 1998). 
1.3.4.2 Dietary 
Earlier studies failed to identify a relationship between supplementary feeding or stage 
of pasture growth and EGS (Doxey et al., 1991a, Wood et al., 1998), but more recently, 
the feeding of hay or haylage has been associated with a decreased risk of disease 
(McCarthy et al., 2004). McCarthy et al. (2004) also reported an increased risk with 
changing of feed type or quantity during the 14 days prior to disease onset.  
1.3.4.3 Movement/ stress 
Animals that had recently moved fields, especially within the preceding 2 weeks, had 
the largest effect in a multivariate model (odds ratio 29.7) (Wood et al., 1998). Of 218 
EGS cases identified in a retrospective survey, 45% had moved from another field or 
premise in the two weeks prior to illness with 12% incurring a stressful event such as 
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castration, foaling and breaking in the two weeks preceding onset of illness (Doxey et 
al., 1991a).  
1.3.4.4 Anthelmintic use  
In comparison to horses receiving anthelmintics ≥ 6 monthly, horses receiving an 
anthelmintic at any greater frequency had an increased risk of recurrence of EGS 
(Newton et al., 2004). The use of ivermectin at both the ultimate and penultimate 
treatments has been associated with an increased risk of EGS (McCarthy et al., 2004).  
1.3.4.5 Removal of faeces   
In one study, the manual removal of horse faeces from pastures significantly reduced 
the risk of recurrence while mechanical removal increased the risk of recurrence of 
EGS (Newton et al., 2004). Again, it was speculated that mechanical removal of faeces 
(e.g. sweeping the paddocks) may disturb the soil surface and possibly disseminate the 
causal agent.  
 
Whilst multiple risk factors have been identified in both univariable and multivariable 
analyses, only a few risk factors have been consistently reported in the literature 
(grazing, age, time of year and recent movement to new pasture). These 
epidemiological findings give insight into the aetiology of the disease and possible 
protective control measures.  
 
1.4 Aetiology  
As the name suggests, the disease almost exclusively affects grazing equids and 
epidemiological studies support the role of an ingested soil-borne agent, which in 
certain circumstances, produces a putative neurotoxin (Pirie et al., 2014). Whilst the 
aetiopathogenesis is yet to be elucidated, likely causes include toxico-infection with 
Clostridium botulinum types C or D (Tocher et al., 1923, Hunter et al., 1999, McCarthy 
et al., 2004, Ireland, 2014) and pasture derived mycotoxins (Doxey et al., 1991b, Robb 
et al., 1997).  
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Botulism was first proposed as the underlying cause of EGS as early as 1918 when 
post-mortem studies isolated bacteria with morphological and toxicity characteristics 
similar to C. botulinum (Tocher et al., 1923). A subsequent vaccination field trial using 
antitoxin-neutralised C. botulinum successfully reduced the incidence of EGS in 
vaccinated horses compared with those receiving placebo (Tocher et al., 1923). 
However, the validity of the study was questioned, and funding was directed elsewhere 
(Newton et al., 2010), until recently when the botulinum theory has been re-
investigated. Whilst an association between C. botulinum type C within the intestinal 
tract and EGS has been confirmed (Hunter et al., 1999), a causal relationship has not 
been proven. Furthermore, a similar difference in detection frequency of C. 
perfringens between EGS and controls has been reported, potentially reflecting a 
generalised clostridial overgrowth in the small intestine of EGS horses secondary to 
pre-existing gastrointestinal dysmotility (Waggett et al., 2010b). McCarthy et al. 
(2004) found that increasing serum antibody titres to C. botulinum type C, C. 
botulinum C1 neurotoxin and C. novyi type A surface antigens were significantly 
associated with a decreased risk of EGS, further evidence of an association between 
C. botulinum and EGS. The outcome of the ongoing nationwide triple blinded 
randomised placebo controlled trial of C. botulinum type C toxoid vaccination will 
support or refute the theory that C. botulinum has an obligatory role in the aetiology 
of EGS (Ireland, 2014, Ireland et al., 2016).  
 
Whilst the particular climatic conditions which often precede occurrences of EGS have 
been considered to be consistent with the involvement of a pasture derived mycotoxin 
(Doxey et al., 1991b), all studies to date have failed to associate any particular fungal 
species with EGS (Doxey et al., 1990). Fusarium spp. which have neurotoxic 
properties in vitro, have been isolated from EGS pastures (Robb et al., 1997). Further 
investigations into the potential role of pasture mycotoxigenic fungi, utilising modern 
molecular techniques, are currently ongoing (B. C. McGorum, personal 
communication).   
 
Other possible aetiologies of EGS that have been discounted include cyanogenic wild 
white clover (Trifolium repens) (Tocher, 1924, McGorum and Anderson, 2002, 
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McGorum et al., 2012), alsike clover (Trifolium hybridum) (Tocher et al., 1923), insect 
vectors (Lloyd, 1934) and niacin deficiency (McGorum et al., 2016a). 
 
1.5 Pathology   
Equine grass sickness is a polyneuropathy affecting the central and autonomic nervous 
systems, with pathological lesions most evident in the paravertebral, prevertebral and 
enteric (submucosal and myenteric) ganglia (Cottrell et al., 1999). The histological 
feature of EGS, first described in 1955, is neuronal degeneration with extensive 
chromatolysis (Obel, 1955), with loss of Nissl substance, cytoplasmic vacuolation, 
eccentric nuclei, nuclear pyknosis, nuclear karyorrhexis, eosinophilic spheroids and 
axonal dystrophy (Obel, 1955, Gilmour, 1975, Scholes et al., 1993b, Whitwell, 1997). 
Neuronal cell death ensues, followed by neuronophagia with a subsequent reduction 
in the number of neurons (Obel, 1955, Brownlee, 1965, Scholes et al., 1993b). Both 
cytoplasmic vacuolation and eccentric nuclei can occur as a normal variation, with the 
former also occurring as a processing artefact (Scholes et al., 1993b).   
1.5.1 Enteric nervous system  
The enteric nervous system comprises the submucosal and myenteric plexuses. The 
submucosal plexus is located in the submucosa between the muscularis mucosae and 
the muscularis externa, giving rise to postganglionic neurons innervating the secretory 
epithelium, blood vessels and smooth muscle of the muscularis mucosae (Furness and 
Costa, 2006). Two separate submucosal plexuses have been identified with an internal 
(Meissner’s) plexus, consisting of smaller ganglia (up to four neurons) adjacent to the 
muscularis mucosae and an external (Henle’s) plexus, consisting of larger (up to 20 
neurons) ganglia, adjacent to the circular muscularis (Scholes et al., 1993b, Pearson, 
1994). This is consistent throughout the small and large intestine, but in the rectum, 
most submucosal ganglia are situated within the inner plexus with adipose tissue 
occupying the outer submucosa (Scholes et al., 1993b). The myenteric (Auerbach) 
plexus is located between the inner circular and outer longitudinal muscularis layers 
and primarily controls gastrointestinal motility (Furness and Costa, 2006).   
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Several studies have reported degeneration and depletion of enteric neurons in cases 
of EGS (Obel, 1955, Barlow, 1969, Pogson et al., 1992, Doxey et al., 1992, Scholes et 
al., 1993b, Doxey et al., 1995b). Neuronal pathology is not uniform throughout the 
gastrointestinal tract (GIT) and Scholes et al. (1993b) were the first to compare severity 
of pathology at different sites. The distribution of neuronal degeneration and neuronal 
depletion was widespread throughout the duodenum, jejunum, caecum, large and small 
colon in acute cases, but only the ileum had consistently severe pathology in CGS 
(Scholes et al., 1993b). With more objective data, Doxey et al. (1995b) confirmed this 
finding, reporting that overall the ileum had significantly greater neuronal depletion 
and proportion of chromatolytic neurons in all three forms of the disease, compared to 
the jejunum and small colon. However, in a minority of acute and subacute cases, the 
most severely affected region was the jejunum (Doxey et al., 1995b). More recently, 
Milne et al. (2010) reported the ileum to consistently be more severely affected than 
the jejunum in 23 cases of EGS.    
Histological examination of the jejunum, however, may facilitate more accurate 
differentiation of the sub-classifications of EGS, since the proportion of chromatolytic 
neurons and the depletion of neurons is greater in the jejunum of acute and subacute 
EGS than in CGS (Pogson et al., 1992, Doxey et al., 1992, Doxey et al., 1995b). 
Although the same pattern is evident in the small colon, it is consistently less obvious 
at this site, compared with the jejunum (Doxey et al., 1995b). This contradicts earlier 
findings by Barlow et al. (Barlow, 1969) who reported a greater degree of neuronal 
depletion in chronic cases, however only 3 chronic cases were compared, and the 
number of neurons was only commented upon subjectively.  
Varying degrees of neuronal pathology are described in the stomach and rectum of 
acute cases, while gastric and rectal neurons of chronic cases have a similar appearance 
to controls (Scholes et al., 1993b). Scholes considered that full thickness rectal 
biopsies may only give a positive diagnosis in a proportion of acute cases (Scholes et 
al., 1993b). 
The numbers of ganglia and total neurons were greater in the submucosal plexus 
compared to the myenteric plexus (Doxey et al., 1992, Doxey et al., 1995b) having 2-
3 times more neurons per section (Doxey et al., 1995b). This could have potential 
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practical advantages when assessing more superficial mucosal/ submucosal biopsies. 
Whilst the submucosal plexus was more severely affected in the ileum (Doxey et al., 
1995b, Milne et al., 2005), the myenteric plexus was more severely affected in the 
jejunum (Pogson et al., 1992, Doxey et al., 1992, Doxey et al., 1995b). The distribution 
of neuronal damage is uniform within each region of the intestine, throughout the 
jejunum, ileum and small colon (Doxey et al., 1995b).  
The interstitial cells of Cajal (ICC), the intrinsic pacemakers of the smooth muscle of 
the intestinal tract (Sanders et al., 2012), are present in reduced numbers in the ileum 
and pelvic flexure of horses with EGS (Hudson et al., 2001).  
1.5.2 Autonomic ganglia  
In addition to the enteric nervous system, neuronal degeneration and depletion is 
evident elsewhere throughout the autonomic nervous system, including the following 
paravertebral ganglia: cranial cervical, caudal cervical and stellate ganglia, and the 
thoracic and abdominal sympathetic trunk. Prevertebral ganglia reported to be affected 
include the cranial (coeliac) mesenteric, caudal mesenteric and the parasympathetic 
terminal cardiac ganglia (Obel, 1955, Brownlee, 1959, Barlow, 1969, Gilmour, 1975, 
Pogson et al., 1992, Doxey et al., 1992, Griffiths et al., 1993, Perkins et al., 2000, John 
et al., 2001, Shotton et al., 2011).   
For all sub-classifications of the disease, the proportion of chromatolytic neurons in 
the paravertebral ganglia is significantly increased compared with control horses, and 
the percentage of chromatolytic neurons increases with the severity of disease (Pogson 
et al., 1992, Doxey et al., 1992). Whilst Pogson et al. (1992) reported that the cranial 
mesenteric ganglia were not as severely affected as cranial cervical ganglia (CCG) in 
acute and subacute EGS, Shotton et al. (2011), utilising immunofluorescence labelling 
techniques, found evidence of greater neurodegeneration in the cranial mesenteric 
ganglia than the CCG, perhaps indicating a greater vulnerability of the prevertebral 
neurons to the putative neurotoxin.  
In contrast to enteric ganglia, multiple studies have demonstrated that the total number 
of neurons is significantly reduced in the autonomic ganglia of CGS, compared to 
acute and subacute EGS (Pogson et al., 1992, Doxey et al., 1992). It was speculated 
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that neuronal depletion occurs in the jejunum of acute cases before neuronal loss has 
occurred in the peripheral ganglia (Pogson et al., 1992).  
No significant differences were demonstrated in the proportion of chromatolytic 
neurons throughout different sections of individual paravertebral ganglia, nor between 
the left and right CCG, while the cranial mesenteric ganglia had a patchy distribution 
of chromatolytic neurons (Pogson et al., 1992). This is relevant when collecting 
samples for histopathological assessment.  
1.5.3 Central nervous system  
Whilst often termed ‘equine dysautonomia’, the evidence for involvement of somatic 
lower motor neurons (LMN) indicates that EGS is more accurately termed as a 
multisystem disease (Barlow, 1969, Gilmour, 1973, Hahn, 2000). Neuronal 
chromatolysis was most consistently noted in the LMN of general visceral efferent 
nuclei of cranial nerves III and X, and the general somatic efferent nuclei of cranial 
nerves III, V, VII and XII (Hahn et al., 2001). Chromatolysis was also reported in 83% 
of the intermediolateral horn LMN and 35% of ventral horn LMN in the spinal cord 
of EGS cases (Hahn et al., 2001).   
Despite the severe chromatolysis of ventral horn LMN, there was no evidence of 
neuronal cell death, axonal pathology or muscle denervation or re-innervation, such as 
muscle fibre type grouping, in somatic muscles innervated by chromatolytic neurons 
(Hahn, 2000). Therefore, in contrast to autonomic ganglion neurons and enteric 
neurons, it appears that chromatolytic central neurons may not progress to cell death 
in EGS and thereby could potentially recover with time. Consistent with this 
possibility, histological assessment of an animal recovered from EGS identified no 
pathological changes in the central nervous system or striated muscle (Milne et al., 
2005).   
1.5.4 Gross post mortem findings  
Gross post mortem findings are largely reflective of the effects of dysautonomia on 
the GIT (Pirie et al., 2014). Acute EGS cases generally have gastric and small intestinal 
fluid distension (Lyle and Pirie, 2009), and possibly gastric rupture and associated 
peritonitis. Firm and corrugated large colon and caecal impactions are present in 
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subacute and some acute cases, with a black coating adhered to the colonic mucosa 
(Pirie, 2006). Chronic EGS cases have a relatively empty GIT, evidence of cachexia, 
rhinitis sicca (Lyle and Pirie, 2009) and possibly aspiration pneumonia. All cases can 
have evidence of reflux oesophagitis, with linear erosions of the distal oesophagus 
(Pirie, 2006). Dry, firm mucus coated faecal balls are also found in the small colon and 
rectum of the majority of subacute and chronic cases (Pirie et al., 2014).  
 
1.6 Ante-mortem diagnosis of equine grass sickness  
Reaching a definitive ante-mortem diagnosis of EGS together with appropriate disease 
sub-classification is not only important for the individual’s prognostication and for 
consideration of treatment options, but also for provision of appropriate advice to 
allow early implementation of management changes for other at-risk co-grazing 
horses.  
An ante-mortem diagnosis of EGS can be made presumptively, after considering the 
nature and progression of clinical signs, subjective ancillary tests, history and 
epidemiological factors, together with the exclusion of differential diagnoses that may 
mimic EGS clinically (Pirie et al., 2014). Milne et al. (1994) and Doxey et al. (1995a) 
found the accuracy of diagnosis of CGS to be 100% on the basis of clinical signs alone. 
However, these clinical evaluations were performed by veterinary surgeons at the 
University of Edinburgh, who have considerable experience in the diagnosis of EGS. 
Whilst the exposure to clinical cases is much higher for veterinary surgeons in eastern 
Scotland (Wood et al., 1998, McCarthy et al., 2001, Wylie et al., 2011), some cases 
referred to the author with a presumptive diagnosis of CGS have been incorrectly 
diagnosed (author, personal observation). The diagnostic accuracy is likely to be lower 
in regions with a low incidence of the disease (Doxey et al., 1995a).  
The desired aim of most diagnostic tests is to achieve 100% sensitivity and specificity 
compared to the gold standard. Relating to EGS, the most important diagnostic 
determinant is specificity, as false positive results may result in unnecessary euthanasia 
of horses erroneously diagnosed with EGS.    
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1.6.1 Ancillary diagnostic tests  
1.6.1.1 Haematology and biochemistry  
Haematology and biochemistry is of limited value in the diagnosis of EGS. Evidence 
of haemoconcentration (increased PCV, serum protein and serum urea) and stress 
(increased cortisol) are evident in acute EGS; however these findings are not unique 
to EGS (Doxey et al., 1991c). Whilst the serum activity of the intestinal isoenzyme of 
alkaline phosphatase was elevated in acute EGS, the mean proportion of intestinal to 
total alkaline phosphatase remained within the normal reference range (Doxey et al., 
1991c). Ten of 15 EGS horses had a mild metabolic alkalosis (Fintl et al., 2002).   
1.6.1.2 Acute phase proteins  
Milne et al. (1991) demonstrated an increase in haptoglobin and orosomucoid in all 
sub-classifications of the disease and in horses with active inflammatory conditions, 
but not in control and non-inflammatory colic cases. Ceruloplasmin and ∝2-
macroglobulin were significantly higher in acute EGS only; thought more likely to 
reflect haemoconcentration (Milne et al., 1991). More recently, significant increases 
in serum amyloid A and fibrinogen were reported in EGS cases compared with healthy 
horses, co-grazers and non-inflammatory colic cases, but levels were not significantly 
different from those of inflammatory colic cases (Copas et al., 2013). Whilst 
fibrinogen and serum amyloid A analysis may have some diagnostic benefits 
differentiating EGS from non-inflammatory small intestinal obstructions, these tests 
have a low specificity differentiating EGS from other inflammatory abdominal 
conditions such as peritonitis, enteritis, colitis and abscessation (Copas et al., 2013).  
1.6.1.3 Biomarkers of neurodegeneration 
Plasma concentrations of the heavily phosphorylated form of major neurofilament 
subunit NF-H mirror the degree of axonal degeneration in some human (Petzold and 
Shaw, 2007) and animal (Shaw et al., 2005) neurodegenerative disorders. However, 
Stratford et al. (2013) did not detect a significant difference between the levels of this 




1.6.1.4 Cytotoxicity testing  
The effects of EGS serum on neuro-2a and genetically engineered PC12 Tet-Off  P53 
cell lines in an in vitro model have been investigated. Serum from 60% of EGS cases 
exerted cytotoxic effects, such as mitochondrial dysfunction, pinocytosis, and reduced 
intracellular ATP-content. The low sensitivity, and impracticality of the equipment 
and time required, questioned the applicability of this ante-mortem, in vitro, diagnostic 
test in practice (Malekinejad et al., 2012).  
1.6.1.5 Urinalysis  
Whilst urinalysis demonstrated some significant differences between EGS and control 
horses which may support a diagnosis of EGS, none of the findings were 
pathognomonic for the disease (Fintl et al., 2002). Horses with EGS had higher urinary 
specific gravity, creatinine concentration (indicative of haemoconcentration) and 
protein. Urine pH was significantly lower in EGS cases compared to control and co-
grazers, and urine glucose concentration was significantly increased in acute EGS 
compared to that of subacute EGS and control and co-grazing horses (Fintl et al., 
2002).   
1.6.1.6 Faecal analysis  
The potential diagnostic value of detecting Clostridium perfringens in the faeces of 
EGS cases has been assessed. Detection of C. perfringens by ELISA in faecal samples 
has a good specificity (93%) but poor sensitivity (41%) for differentiating EGS and 
colic cases (Waggett et al., 2010b).   
1.6.1.7 Peritoneal fluid analysis  
Peritoneal fluid analytes have been compared in medical and surgical colic, acute and 
subacute EGS, and control cases. Equine grass sickness cases had a higher specific 
gravity and protein content than the cases of medical colic. The presence of 
serosanguinous fluid and high alkaline phosphatase was unique to surgical colic cases 




1.6.1.8 Phenylephrine eye drops  
Resting tone of the upper eyelid is supplied by Müller’s superior tarsal muscle, a 
smooth muscle innervated by sympathetic axons, with second order neurons in the 
CCG (Hahn and Mayhew, 2000b). Bilateral ptosis is a recognised feature of EGS (Pirie 
et al., 2014). Reversal of ptosis following the administration of 0.5% phenylephrine 
(α1 agonist) to the conjunctival sac confirms the presence of smooth muscle paralysis 
underlying the ptosis (differentiating from somatic nerve dysfunction), providing 
evidence to support sympathetic dysfunction in suspected cases of EGS (Hahn and 
Mayhew, 2000a). However, false positives do occur, especially in sedated horses.  
1.6.1.9 Electromyography  
As alluded to earlier, EGS results in chromatolysis of many LMN (Hahn et al., 2001). 
Wijnberg et al. (2006) demonstrated some evidence of neuropathy of skeletal muscles 
in horses suspected to have EGS by electromyography, and proposed that the 
combination of clinical and electrophysiological evidence may aid the diagnosis of 
neurogenic disease in cases of weight loss and colic.  
1.6.1.10 Oesophageal motility  
In addition to oral and pharyngeal components, it has been proposed that the dysphagia 
observed in cases of EGS is attributed in part to oesophageal dysfunction (Cottrell et 
al., 1999). Oesophageal dysfunction was demonstrated by a barium swallow test in all 
18 confirmed EGS cases (Greet and Whitwell, 1986); thereby providing supportive 
evidence for the diagnosis.   
 
Whilst numerous ancillary diagnostic tests for EGS have been evaluated, some tests 
provide no diagnostic valve, some provide supporting evidence for the diagnosis of 
EGS, but none have, or even approach, 100% specificity or sensitivity. Furthermore, 





1.6.2 Histopathological examination of ileum  
At present, a definitive ante-mortem diagnosis is only made following 
histopathological examination of enteric ganglia (Obel, 1955, Barlow, 1969, Pogson 
et al., 1992, Doxey et al., 1992, Scholes et al., 1993b, Doxey et al., 1995b). 
Strangulating and non-strangulating small intestinal obstructions comprise the 
principal differential diagnoses for acute EGS (Lyle and Pirie, 2009) and in addition 
to facilitating the collection of an ileal biopsy, surgical exploration of the abdomen in 
such cases permits the exclusion of such lesions as diagnostic candidates.  
Whilst the accuracy of diagnosis of acute EGS has not been reported, in the majority 
of cases, a clinician experienced in the diagnosis of EGS can differentiate an acute 
case of EGS from its principal diagnosis, namely physical obstruction of the small 
intestine. However, if clinical findings are equivocal, an exploratory laparotomy is 
recommended to provide owners with further definitive confirmation of diagnosis, 
and, where appropriate, to provide a definitive diagnosis to support an insurance claim 
for mortality. In the absence of a physical small intestinal obstruction, many horses are 
euthanased prior to recovery from anaesthesia, before the results of ileal 
histopathology are available (author, personal observations). In such cases, results of 
histopathological examination can at best only support the diagnosis retrospectively.  
1.6.2.1 Haematoxylin and eosin stained formalin fixed sections of 
ileum  
Examination of haematoxylin and eosin (H&E) stained, formalin fixed full thickness 
ileal biopsies, has long been considered the best method for ante-mortem diagnosis of 
EGS (Scholes et al., 1993a, Scholes et al., 1993b, Doxey et al., 1995b, Murray et al., 
1997). Critical evaluation by Milne et al. (2010) found that 1cm long, full thickness 
ileal biopsies, collected post-mortem from 23 cases of EGS and 11 of colic, yielded a 
sensitivity and specificity of 100% for the diagnosis of EGS, when compared against 





1.6.2.2 Haematoxylin and eosin stained frozen sections of ileum  
Histopathological assessment of frozen (cryostat) sections rather than formalin-fixed 
sections has the distinct advantage that the diagnosis may be obtained intraoperatively, 
abolishing the need to recover the horse from general anaesthesia and continue 
supportive care until a definitive diagnosis of EGS is confirmed or refuted. Cryostat 
sections of ileum had a sensitivity of 100% and specificity of only 73% for diagnosis 
of EGS, meaning that a significant proportion of cases would have been misclassified, 
resulting in inappropriate euthanasia (Milne et al., 2010). Diagnostic errors may reflect 
freeze artefacts that can mimic neurodegeneration (Milne et al., 2010).  
1.6.2.3 Synaptophysin immunolabelling 
Synaptophysin is the major membrane protein of synaptic vesicles and is specifically 
expressed in neuroendocrine tissue (Thiel, 1993). Synaptophysin 
immunohistochemistry was used to identify accumulation of synaptophysin in 
degenerating neuronal perikarya in autonomic ganglion and intestinal samples from 6 
EGS cases, compared with samples from 4 control horses (Hilbe et al., 2005). Whilst 
the neuronal perikarya from healthy horses were mainly negative for synaptophysin, a 
few perikarya showed homogenous faint labelling, and labelling was present around 
ganglion cells and in the axons of control cases (Hilbe et al., 2005).  
Waggett et al. (2010a) further evaluated synaptophysin immunolabelling of ileal 
sections for EGS diagnosis using a larger sample size (20 EGS and 24 control cases) 
and including a control group of colic cases. Whilst most samples from EGS cases 
with identifiable submucosal and myenteric plexus neurons had marked synaptophysin 
labelling, complete differentiation of EGS cases from control cases was only possible 
when including assessment of neuronal density and utilising a decision tree (Waggett 
et al., 2010a). 
1.6.3 Alternative biopsy locations 
Performing a laparotomy in a suspected CGS case to confirm the diagnosis invariably 
compromises the likelihood of survival (Doxey et al., 1995a, Doxey et al., 1998) and 
increases costs. A similar deterioration occurs in cats with dysautonomia which 
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undergo laparotomy (Milne et al., 1994). Despite this concern, some veterinary 
hospitals will perform midline laparotomies (Mellor et al., 2013) or standing flank 
laparotomies to confirm the diagnosis of CGS.  
In suspected cases, particularly subacute and chronic cases, where exploratory 
laparotomy is neither feasible nor clinically indicated, consideration should be given 
to other appropriate biopsy sites, histopathological examination of which might permit 
accurate diagnosis.  
1.6.3.1 Immunohistochemistry of nasal mucosa 
Prince et al. (2003) investigated the ante-mortem diagnostic value of measuring the 
expression of nonadrenergic noncholinergic neurotransmitters as neuronal markers in 
nasal mucosal samples from EGS cases. The density of innervation was reduced for 
all four neuronal markers in chronic cases, compared to acute cases and control horses. 
The changes in innervation determined in this study may reflect the mechanisms 
underlying the clinical presentation of rhinitis sicca noted in CGS. However as 
discussed by Pirie et al. (2014) there is less urgency with regards to the diagnosis of 
chronic cases and simple visual identification of rhinitis sicca is generally considered 
pathognomonic for EGS (Lyle and Pirie, 2009). 
1.6.3.2 Haematoxylin and eosin stained biopsies of gustatory papillae   
McGorum et al. (2015a) achieved 100% sensitivity and 98.2% specificity for 
diagnosing EGS by the presence of chromatolysis in blinded H&E stained post-
mortem sections of subgemmal plexi. Whilst samples from 2 horses were collected 
post-mortem as ‘simulated biopsies’ using uterine biopsy forceps after the placement 
of an oral gag, further validation is required to determine the utility of this method in 
the pre-mortem diagnosis of EGS. However, the presence of a mixture of 
chromatolytic and normal neurons in 1/57 sections from one of the 13 control horses 
indicates that chromatolysis of subgemmal neurons is not pathognomonic for EGS 





1.6.3.3 Haematoxylin and eosin stained rectal submucosa 
In contrast to nasal and tongue biopsies, rectal biopsies are already commonly utilised 
for other diagnostic reasons (Lindberg et al., 1996), and are known to be safe, 
straightforward, inexpensive and minimally invasive (Ricketts, 1996). Furthermore, 
chromatolytic neurons have already been identified in rectal submucosa in EGS horses 
(Scholes et al., 1993b, Doxey et al., 1995b, Wales and Whitwell, 2006, Mair et al., 
2011). Histological examination of full-thickness, H&E stained, post-mortem rectal 
samples yielded a sensitivity of 71% and specificity of 100% for EGS diagnosis, when 
the diagnostic criterion was identification of at least three neurons with complete 
chromatolysis within the submucosal plexus (Wales and Whitwell, 2006). The number 
of neurons in individual biopsies varied markedly and only a few neurons were 
observed in any one section (10mm length and 4mm width) in 9 out of 24 horses, the 
yield of which could not be maximised by sampling from a particular circumferential 
site (Wales and Whitwell, 2006). Whilst neuronal depletion is reported in the small 
intestine of horses with EGS (Pogson et al., 1992, Doxey et al., 1992, Scholes et al., 
1993b, Doxey et al., 1995b), a low neuronal count in the submucosal plexus of rectal 
samples did not appear to correlate with EGS diagnosis, but more likely reflected 
general paucity of neurons in the rectal submucosal ganglia (Wales and Whitwell, 
2006). Staining rectal sections with cresyl fast violet and methyl green-lyronin did not 
improve the diagnostic value (Wales and Whitwell, 2006).  
A later study, utilising uterine biopsy forceps for the collection of partial thickness, 
H&E stained samples, revealed a sensitivity of only 21% for EGS diagnosis (Mair et 
al., 2011). The high proportion of inconclusive results was primarily due to an inability 
to identify reliably sufficient numbers of neurons in the samples that contained only 
the internal ganglia of the submucosal plexus (Mair et al., 2011). In contrast, the post-
mortem samples collected by Wales and Whitwell (2006) were full thickness, and thus 
contained both the internal and external ganglia of the submucosal plexus. Diagnosis 
may also be potentially limited by difficulty in histological recognition of 
chromatolytic neurons and crush artefacts. It was suggested that application of specific 
neuronal labelling may increase the diagnostic sensitivity of rectal biopsies in EGS 
diagnosis (Mair et al., 2011).  
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1.7 Treatment of equine grass sickness 
With appropriate supportive nursing care a proportion of CGS cases survive (Milne et 
al., 1994, Doxey et al., 1995a, Doxey et al., 1998, Doxey et al., 1999, Wylie et al., 
2011). Criteria that have been applied to select cases suitable for treatment include; 
some appetite, an ability to drink and swallow feed and absence of continuous colic 
signs (Doxey et al., 1995c). One of the greatest obstacles to a favourable outcome is 
the profound inappetance (Pirie et al., 2014) and cases should be regularly offered a 
wide variety of highly palatable concentrate feeds of varying consistencies, as food 
preferences change frequently (Doxey et al., 1995c). Bolus and continuous-flow 
enteral feeding together with partial and total parenteral nutrition have been used in a 
few selected cases (Pirie and Jago, 2015). Whilst this may reduce the degree of weight 
loss and provide a period of time for spontaneous improvement in appetite and 
reduction in dysphagia, usually the requirement for such nutritional support reflects 
the severity of the disease and there is currently insufficient evidence to suggest that 
these forms of nutritional support alter case outcome (Pirie et al., 2014). Both enteral 
and parenteral nutrition are expensive and associated with multiple potential 
complications (Pirie and Jago, 2015). In cases that are not too weak, daily walking or 
pasture turnout can help improve demeanour, appetite and dislodgement of rhinitis 
sicca plaques (Pirie et al., 2014).  
As some morphologically normal neurons remain in the myenteric plexus of the GIT 
in CGS (Scholes et al., 1993b, Doxey et al., 1995b) it was speculated that the prokinetic 
agent cisapride might be of therapeutic benefit (Milne et al., 1996). While cisapride 
increased the rate of passage of digesta and dry matter intake in cases of CGS (Milne 
et al., 1996), whether this improved survival rate was not determined. This drug is no 
longer available for the treatment of horses. Brotizolam (an appetite stimulant), 
acetylcysteine (an antioxidant and neuroprotectant) and aloe vera gel (a plant extract 
with antioxidant and anti-inflammatory properties) were evaluated as ancillary 
treatments in 29 cases of CGS; none of the treatments appeared to have any significant 
benefits (Fintl and McGorum, 2002). Analgesics and hyoscine may be administered to 
CGS horses to control colic, while omeprazole may be administered to cases that have 
gastric ulceration and reflux oesophagitis (Pirie et al., 2014). Close monitoring of CGS 
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cases is also required, to detect reduced faecal output associated with rectal impactions 
that may require manual rectal evacuation. Close monitoring is also required to detect 
aspiration pneumonia, a relatively common complication of CGS that can be difficult 
to detect due to the frequent absence of localising signs, such as a coughing or nasal 
discharge. Furthermore the associated pyrexia and dullness may be absent because of 
concurrent treatment with non-steroidal anti-inflammatories drugs (author, personal 
observation).  
 
1.8 Prognosis  
While acute and subacute EGS is invariably fatal, some cases of CGS survive (Milne 
et al., 1994, Doxey et al., 1995a, Doxey et al., 1998, Doxey et al., 1999, Wylie et al., 
2011). The overall survival rate for EGS in a 10 year nationwide surveillance scheme 
was 16%, and 49% for cases of CGS (Wylie et al., 2011). The survival rate for 
hospitalised cases of EGS has previously been reported as slightly lower, at 42.7% 
(Doxey et al., 1995a) and 35.6% (Milne et al., 1994).  
Regional variations in survival rate have been reported with cases of CGS in Scotland 
being more likely to survive (odds ratio 1.7) than those occurring elsewhere in Great 
Britain; speculated to be due to variation in expertise of care, application of appropriate 
case selection criteria and/ or disease severity (Wylie et al., 2011). This regional 
difference in survival rate may also be due to regional perceptions for prognosis of 
return to previous ridden work, because this may influence the decision to euthanise a 
horse with EGS. A previous study observed ponies to be significantly less likely to 
survive than Cob types (Milne et al., 1994), whereas the 10 year nationwide 
surveillance scheme identified no significant associations between survival and 
signalment (Wylie et al., 2011). Doxey et al. (1998) also found that Cobs, together 
with Thoroughbreds, had a higher survival rate, while age and sex had no significant 
effect on survival. However, this study comprised only 31 recovered cases. Wylie et 
al. (2011) reported that neither the category of EGS nor the outcome of CGS was 
significantly associated with age, gender, breed, season or year of diagnosis; except 
that cases of CGS diagnosed in June were more likely to survive than those diagnosed 
in May.  
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As previously alluded to, since the extent of neuronal damage is of a continuum scale, 
the clinical sub-classifications should also be thought of as such. This is not only 
applicable to the three sub-classifications but also to the surviving and non-surviving 
CGS cases. It may be relatively easy to predict the outcome of chronic cases that fall 
at either end of this continuum of severity. For example, a severe case that is 
completely anorexic, with severe dysphagia, weakness and inability to stand, is 
unlikely to survive while a mild case with only a slight reduction in appetite is likely 
to survive. In contrast, it is more difficult to predict the outcome of cases in the middle 
of the continuum of disease severity. Moreover, cases of CGS rarely die, being 
typically subjected to euthanasia hopefully before their welfare is compromised. 
Ideally, euthanasia should be done before these cases are recumbent and unable to 
stand, but the time at which this may occur is difficult to predict. Some cases are 
subjected to euthanasia a few months after CGS has been diagnosed (Doxey et al., 
1995a); this is expensive and emotional for owners. Accurate prediction of outcome 
would have welfare and economic benefits because it could reduce the number of 
potential survivors (S) which are subjected to euthanasia and the number of non-
survivors (NS) which are subjected to predictably fruitless attempts at intensive 
nursing prior to euthanasia.  
Only one previous study has investigated potential clinical factors relating to survival 
of CGS. It was demonstrated that non-survival was associated with a higher clinical 
score of dysphagia, anorexia, colic and reduction in intestinal sounds (Milne et al., 
1994); clinical signs which may be associated with the degree of neuronal damage. 
Whilst there was no significant difference between the average rhinitis scores of the 
two groups, 10 of the 29 NS, but none of the 16 S, had severe rhinitis. No significant 
differences were identified between S and NS with regards to sweating and muscle 
fasciculations (Milne et al., 1994). These indices are subjective however and currently 
no objective criteria for predicting the outcome of CGS cases is available.  
In an attempt to predict how long a surviving case of CGS takes to return to clinical 
normality, using duration of hospitalisation as a proxy for the severity of CGS, Doxey 
et al. (1999) failed to identify any association between the duration of hospitalisation 
and the final quality of life of the patient. Multiple factors will affect the duration of 
hospitalisation, including finances, owner’s desire to have the patient return home, and 
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disease stage at time of admission. Furthermore, in this study, the final quality of life 
of the patient was subjectively analysed by the owners. However, duration of 
hospitalisation had a relationship with the return to normal body weight, with horses 
which had average hospital stays of 8.3 and 45.3 days having an average time for return 
to normal bodyweight of 4.5 and 6.9 months respectively (Doxey et al., 1999).  
1.8.1 Long-term outcome of recovered chronic grass sickness cases  
It would be expected that, subsequent to chromatolysis, necrosis and depletion of 
enteric neurons, the associated dysfunction of the GIT would be irreversible. However, 
Milne et al. (1994) reported that dysphagia and reduced gut sounds gradually improved 
in S. Enteric neurons cannot regenerate and it is speculated that a process of 
compensation, involving the reorganisation of remaining neurons, occurs (Milne et al., 
1994).    
Horses required between 3 and 18 months before returning to their original weight 
following hospital discharge (Doxey et al., 1995a) and on average took 12 months 
before starting ridden work (Doxey et al., 1998). All S in multiple studies resumed 
ridden work (Milne et al., 1994, Doxey et al., 1995a, Doxey et al., 1998), with up to 
81% returning to competition level (Doxey et al., 1995a, Doxey et al., 1998). Despite 
returning to a normal body weight, some horses continue to have excessive sweating 
(65%), coat changes (58%), difficulties in swallowing some feed (48%), and mild 
recurrent colic (23%) (Doxey et al., 1998). The sweating observed in the recovered 
horses was generally associated with excitement (Doxey et al., 1995a, Doxey et al., 
1998). Hair coat changes included abnormal retention of the winter coat and small 
areas of piloerection, while oesophageal choke was always related to changes in the 
feeding regimen e.g. introduction of dry fibrous food (Doxey et al., 1995a, Doxey et 
al., 1998).  
A significant loss of enteric neurons was evident in ileal myenteric and submucosal 
plexuses of horses that recovered from CGS between 11 months to 13 years previously 
(Doxey et al., 2000, Milne et al., 2005). There was a dramatic reduction in the number 
of morphologically normal neurons in the ileum of recovered horses (mean number of 
0.47 submucosal neurons per cm of circumference in the ileum of recovered horse 
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compared to 29.4 in healthy control horses), and a less marked reduction in the number 
of neurons in the jejunum (Doxey et al., 2000).   
Whilst there is a reduction in numbers of ICC in the ileum of horses with EGS of all 
sub-classifications (Hudson et al., 2001), immunohistochemistry revealed a 
continuous network of ICC in a single recovered case of CGS (Milne et al., 2005). It 
has been demonstrated that dysfunctional ICC can recover or regain a functional 
phenotype (Der et al., 2000, Chang et al., 2001). It is speculated that whilst the enteric 
neurons are permanently depleted, recovered horses no longer demonstrate significant 
clinical evidence of GIT dysfunction because the ICC recover and compensate for the 
loss of enteric neurons (Milne et al., 2005).             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
1.9 Bodyweight loss 
Bodyweight loss, potentially resulting from anorexia, dysphagia, rhinitis sicca, loss of 
taste sensation and cachexia, is a prominent feature of CGS (Hudson and Pirie, 2005, 
Wylie and Proudman, 2009, Pirie et al., 2014, McGorum et al., 2015a) and is one of 
the few potentially prognostic clinical parameters that can be measured objectively.  
Median weight loss as a percentage of initial hospitalised bodyweight for 34 cases of 
CGS was 5.2% (including cases that did not lose weight) (Doxey et al., 1995a). Doxey 
et al. (1995a) reported that those hospitalised CGS cases that lost most weight 
generally took longer to regain body weight and were more likely to have residual 
problems, but they were not necessarily more likely to die. However, the NS included 
in this study (4 out of 34) were those that died at home following discharge from the 
hospital, and no horses subjected to euthanasia in the hospital were included for 
comparison. Whilst the body weight loss as a percentage of initial body weight was 
not compared between S and NS, most likely due to the small number of NS (n = 4), 
interestingly the horse with the greatest percentage of weight loss (21.5%) was a NS 
(Doxey et al., 1995a). The median duration of hospitalisation for this study was 31 
days, and all horses which lost more than 10% of their body weight were hospitalised 




1.10 Aims of the studies  
The global motivation for the study was to increase the accuracy of diagnosis and 
prognostication for EGS. An accurate, minimally invasive, ante-mortem diagnostic 
test for EGS is currently lacking and currently there are no objective criteria for 
predicting the outcome of CGS cases.  
The specific aims of the studies were therefore: 
1. a.  To determine if submucosal rectal biopsies immunolabelled for β-amyloid 
precursor protein (β-APP) could provide an accurate ante-mortem test for EGS 
diagnosis. 
b.  To develop and refine a grading scheme for assessing the distribution and 
intensity of β-APP immunoreactivity within individual neuronal perikarya and 
axons in rectal submucosal biopsies and subsequently determine the best 
diagnostic predictor for discriminating EGS and control horses.  
2. To determine whether the rate and/ or magnitude of bodyweight change during 
hospitalisation of CGS cases can provide an objective predictor of survival to 












2 Chapter Two: Histological assessment of β-
amyloid precursor protein immunolabelled rectal 
biopsies aids diagnosis of equine grass sickness 
 
2.1 Introduction 
β-amyloid precursor protein is an extensively post-translationally modified and 
proteolytically cleaved transmembrane protein, associated with synaptic formation and 
repair, present at high concentrations within neurons (Muresan and Muresan, 2015). 
Increased β-APP expression is part of the acute phase response to neuronal injury 
(Roberts et al., 1994), occurring in acquired diseases (Finnie et al., 2000, Mete et al., 
2013), in various neurodegenerative conditions (Hanshaw et al., 2015) including 
Alzheimer’s disease (Salminen et al., 2013), Down’s Syndrome (Bandyopadhyay et 
al., 2013) and tauopathies (Irwin et al., 2013) and in murine neurodegenerative disease 
models (Kokjohn and Roher, 2009). β-amyloid precursor protein has been shown to 
accumulate in CCG neuronal perikarya in EGS (McGorum et al., 2015b).  
 
2.2 Hypothesis 
This study tested the hypothesis that immunolabelling with β-APP would improve the 
accuracy of histological assessment of rectal biopsies for EGS diagnosis.  
 
2.3 Materials and methods  
Histopathological examination of formalin-fixed, H&E stained CCG is regarded as the 
“gold standard” diagnostic test for EGS (Doxey et al., 1995b, Pogson et al., 1992, 
Doxey et al., 1992), and β-APP has already been shown to accumulate in CCG 
neuronal perikarya in EGS (McGorum et al., 2015b). Histopathological examination 
of formalin-fixed, H&E stained ileal sections offers 100% sensitivity and specificity 
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(Milne et al., 2010) and has long been considered the best anatomical site for the ante-
mortem diagnosis of EGS (Scholes et al., 1993a, Scholes et al., 1993b, Doxey et al., 
1995b, Murray et al., 1997). A grading scheme was initially developed and applied to 
ileal and CCG samples, to assess the potential sensitivity and specificity of β-APP in 
EGS diagnosis and to validate the grading scheme, using tissues that yield 100% 
sensitivity and specificity for EGS diagnosis, prior to its application in rectal biopsies.   
2.3.1 Collection of tissue samples  
Tissue samples were collected ante-mortem from EGS and control horses for routine 
clinical diagnostic purposes or, with the horse owners’ consent, post-mortem from 
horses subjected to euthanasia. All ileal (McGorum et al., 2016b), CCG (McGorum et 
al., 2015b, McGorum et al., 2016b) and some EGS rectal biopsies (Mair et al., 2011) 
were available from previously reported studies. All the control and remaining EGS 
rectal biopsies were collected prospectively. Horses were of mixed breeds and gender. 
EGS was confirmed by post-mortem examination including conventional 
histopathological examination of H&E stained CCG and/ or ileum (Pogson et al., 1992, 
Doxey et al., 1992, Doxey et al., 1995b, Milne et al., 2010, Gilmour, 1973, Scholes et 
al., 1993a), by specialist pathologists experienced in EGS diagnosis. EGS was 
categorised as previously described (McGorum and Kirk, 2001, Pirie et al., 2014). In 
summary, acute EGS cases had mild to moderate abdominal pain with gastric and 
small intestinal distension, subacute EGS cases had less severe signs, a more insidious 
onset and secondary large intestinal impactions, and chronic cases had none of these 
sequelae. All control cases with colic had a physical lesion identified at exploratory 
laparotomy. All other control horses had no ante-mortem clinical evidence of EGS and 
were subjected to euthanasia for unrelated reasons (see results). Thorough clinical 
examinations were performed, by clinicians experienced in EGS diagnosis, and 
specifically there was no evidence of tachycardia, ptosis, muscle fasciculations, patchy 
sweating, dysphagia, base narrow stance or weight loss with ‘tucked up’ abdominal 
silhouette. The reported median age for EGS horses of 5 years (Jago et al., 2015) was 
considered when selecting cases for control rectal biopsies, such that there would be 
no significant inter-group difference in age. CCG and full thickness ileal samples were 
collected post-mortem within 3.5 h of death. Rectal biopsies were collected using 
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uterine biopsy forcepsa as described previously (Mair et al., 2011). Post-mortem rectal 
biopsies were collected within 10 min of death. Tissues were fixed in 10% neutral 
buffered formalin, embedded in paraffin wax, and 4μm sections cut. A single section 
from each rectal biopsy contributed to a single histology slide for each horse.  
2.3.2 Immunolabelling methodology  
Formalin-fixed, paraffin wax-embedded tissues were dewaxed and rehydrated. 
Antigen retrieval was performed by microwave heating (96oC) sections immersed in 
citrate buffer (pH 6.0, 0.1 M) for 10 min, before cooling for 20 min. A commercial 
immunolabelling kitb was used according to manufacturer’s instructions. Slides were 
rinsed with Tris buffered saline containing 0.5 M Tween pH 7.5 (TBST) and incubated 
with peroxidase blocking agentc for 10 min. Slides were rinsed in TBST and incubated 
with mouse anti-alzheimer precursor protein antibodyd, at 1:16K for 2 h at room 
temperature. Method control sections were prepared for all labelled sections, by 
replacing primary antibody with TBST (for ileum) and with normal mouse serum (for 
rectal biopsies). Slides were rinsed and incubated with horseradish peroxidase-labelled 
polymer for 30 min, then rinsed and incubated with substrate chromogen solutione for 
10 min. Slides were rinsed once in distilled water, counterstained with Harris’s 
haematoxylin for 1 min, dipped in Scott’s   tap water substitute, dehydrated, cleared 
using ethanol then xylene and mounted under DPX.  
2.3.3 Grading of neuronal and axonal immunolabelling  
2.3.3.1 Cranial cervical ganglia and ileum 
Initially a grading scheme was developed by assessing the distribution and intensity of 
immunolabelling of individual neuronal perikarya and axons (Fig 2.1) in randomly 
selected fields of CCG and ileal sections from a subset of EGS and control horses. The 
grading scheme was then blindly applied to all sections of CCG and ileum. CCG 
sections were assessed by grading all individual neurons in five different randomly 
selected fields (x40 objective) of each section. Ileal sections were assessed by grading 




Fig 2.1a: Grading scheme used to assess β-amyloid precursor protein (β-APP) 
immunolabelling of neuronal perikarya in cranial cervical ganglia (CCG) and ileal sections 
(bar = 25µm).  Grade 0= no labelling; 1= low intensity punctate labelling, but underlying 
cytoplasm unlabelled; 2= moderate intensity, non-punctate labelling, often appearing as a 
peripheral halo, but labelling less than 50% of cell; 3= intense labelling of more than 50% of 
cell.  
 
Fig 2.1b: Grading scheme used to assess β-APP immunolabelling of axons in CCG and ileal 
sections (bar = 10µm). Grade 0= no axon labelling; 1= moderate axon (arrow) labelling; 2= 
intense axon (arrow) labelling. 
 
2.3.3.2 Rectum 
Preliminary screening of rectal samples indicated that the grading scheme developed 
using the CCG and ileal sections was insufficiently precise to facilitate repeatable and 
objective grading of the immunolabelling of individual neurons, and in particular to 
unambiguously differentiate grade 2 and grade 3 neurons. Further refinement of the 
grading scheme to facilitate objective assessment of the intensity and distribution of 
immunolabelling of individual neurons was achieved by detailed assessment of the 
immunolabelling of individual neurons in a randomly selected subset of rectal sections, 
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with no regard to disease status. Consequently, the derivation of the neurons (i.e. EGS 
or control horses) had no bearing on the grading refinement process. When applying 
the refined grading scheme, grade 3 neurons, in contrast to grade 2 neurons, were 
classified as those with diffuse labelling of the entire cytoplasm, extending right up to 
the perikaryonal margin, except when this was displaced by cytoplasmic vacuolation 
(Fig 2.2 & 2.3). This grading system was then applied by the author in the blinded 
assessment of all rectal biopsy sections. In all sections, all submucosal plexus neurons 
containing nuclei were graded, identifying neurons with x10 objective and grading 
individual neurons with x40 objective.  
 
  
Grade 0 Grade 1 
  
Grade 2 Grade 3 
Fig 2.2: Grading scheme used to assess β-amyloid precursor protein immunolabelling of 
neuronal perikarya in rectal submucosal plexi. Grade 0= no labelling; 1= sparse labelling 
involving less than half of the cytoplasm; 2= greater than half of the cytoplasm is labelled but 
areas of unlabelled cytoplasm are still discernible; and 3= diffuse labelling of entire cytoplasm 






       2.3a.   
  
            2.3b.             2.3c.  
 
Fig 2.3: Examples of potential grading errors (bars = 10µm).  
a. Two definitive grade 3 neurons with labelling of the entire cytoplasm right up to the 
perikaryonal margin and surrounding the nucleus [green arrow], with an adjacent grade 2 
neuron with faint basophilic cytoplasm in the background [red arrow] 
b. Whilst this neuron does not have labelling extending right up to the perikaryonal margin, 
this is due to vacuolation of the peripheral cytoplasm. The cytoplasmic membrane itself is 
labelled and this neuron would be classified grade 3. 




2.3.4 Data analysis 
Age, number of rectal biopsies per horse and number of neurons counted per horse 
were described using medians and interquartile ranges (IQR). For each horse, the 
distribution of different grades of neuron was determined and a weighted 
immunoreactivity grade calculated. The weighted immunoreactivity grade was the 
sum of each numerical grade multiplied by its percentage prevalence, and divided by 
100. Mann-Whitney U test was used for inter-group (control vs EGS, ante-mortem vs 
post-mortem sample collection, chronic vs subacute vs acute) comparisons of these 
variables. Using conventional histopathological examination of H&E stained CCG 
(Doxey et al., 1992, Doxey et al., 1995b, Pogson et al., 1992, Gilmour, 1973) and 
ileum (Scholes et al., 1993a, Milne et al., 2010) as the reference tests for EGS 
diagnosis, the sensitivity and specificity of EGS diagnosis using histological 
assessment of β-APP immunoreactivity of rectal biopsies was calculated. The 
predictive value of the distribution of different grades of neurons and of the weighted 
immunoreactivity grade for EGS diagnosis was determined by constructing receiver 
operating characteristic (ROC) curves including estimation of area under the curve 
(AUC). An optimal cut-off was proposed by identifying a point that would give 
maximum sensitivity with an estimated specificity of 1.0. A specificity of 1.0 was 
selected (i.e. no false positives within the study data) to minimise the possibility of an 
erroneously diagnosed EGS horse being inappropriately euthanised. The number of 
neurons required to be evaluated per horse to be confident that a grade 3 neuron was 
or was not present, at the expected median prevalence was calculated using a 
surveillance design toolf. The total estimated number of neurons within the rectum 
required for this calculation was calculated assuming that neuronal density is uniform 
throughout the length of the rectum (Doxey et al., 1995b), the diameter of submucosal 
neuronal perikarya was 25μm, and rectal length and diameter was 30 and 7cm 
respectively (Sisson and Grossman, 1975). GraphPad Prismg was used for all other 
statistical analyses. P<0.05 was used as the threshold for statistical significance. This 
study conformed to Standards for the Reporting of Diagnostic Accuracy (STARD) 





2.4.1 Cranial cervical ganglion sections 
Most neurons from control horses were graded 0-1, limited to low intensity punctate 
labelling and occasional labelling of adjacent nerve processes and larger diameter 
nerve fibres, with very little labelling of larger nerve fascicles. Very occasional control 
neurons were grade 2. In contrast, many perikarya from EGS horses had intense (grade 
3) labelling of degenerating neurones and adjacent nerve processes and axons but very 
little labelling of larger nerve fascicles (Table 2.1 & Fig 2.4). Using the presence of 
grade 3 neurons as the criterion for EGS diagnosis yielded a sensitivity and specificity 
of 100%.  
 























Control  153 63 37 0 0 0 
  147 67 33 0 0 0 
  171 47 50 3 0 0 
  148 43 56 1 0 0 
  169 50 49 1 0 0 
Acute grass sickness 183 3 14 42 41 1 
















Table 2.1: Total number of neurons counted in cranial cervical ganglia sections with grades of 
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                 2.4b.  
Fig 2.4: Representative images of β-amyloid precursor protein immunolabelling of cranial 





2.4.2 Ileal sections  
Differentiation of EGS and control ileal sections was readily achieved because all EGS 
sections had grade >2 submucosal and/or myenteric neurons, while all neurons from 
control horses were grade <2 (data not shown). Since the presence of grade >2 neurons 
correctly diagnosed EGS with sensitivity and specificity of 100%, further assessment 
and analysis of the distribution of different grades of individual neurons was not done.  
2.4.3 Rectal biopsy sections  
Rectal biopsies comprised 21 EGS (6 acute, 12 subacute and 3 chronic) and 23 control 
horses. Eight EGS samples were collected ante-mortem and the remainder post-
mortem. Samples from two control horses were collected ante-mortem and the 
remainder post-mortem. Reasons for euthanasia for controls collected post-mortem 
were behavioural (n=1), colic (n=4), neurological (n=4), recurrent uveitis (n=1), 
orthopaedic (n=7) and elderly horses donated for research (n=4). There was no 
significant difference in age of control and EGS horses from which rectal biopsies 
were collected (Fig 2.5).  
All rectal biopsy sections comprised mucosa, submucosa with the submucosal plexus, 
but no myenteric plexus. Significantly more rectal biopsies were collected from 
controls (median 4; IQR 4-5) than from EGS horses (median 2; IQR 2-2), resulting in 
a significantly higher total number of neurons counted in control sections (median 187; 
IQR 111-308) than in EGS sections (median 70; IQR 46-115). However, average 
number of neurons per section was not significantly different between EGS (median 










































































































EGS horses had significantly lower percentages of grade 0 neurons and significantly 
higher percentages of grade 1, 2 and 3 neurons (Table 2.2 & 2.3, Fig 2.6 & 2.7). Grade 
3 neurons were not observed in control horses, but were observed in all but one EGS 
case. Very occasional adjacent nerve processes were labelled, but none were detected 
in the mucosa.  
There was no overlap in the weighted immunoreactivity grade for neurons in EGS and 
control horses, with a value exceeding 1.1 being indicative of EGS. Consequently, the 
AUC of the ROC curves was highest for weighted immunoreactivity grades, lowest 
for grade 1 neurons which had the greatest degree of overlap between EGS and control 
horses, and similar for the other diagnostic determinants (Table 2.3). When the 
specificity was set at 1.0, the highest diagnostic sensitivity for EGS diagnosis was a 
weighted immunoreactivity grade exceeding 1.1 (1.0 sensitivity) and a percentage of 
grade 3 neurons exceeding 0.75% (0.95 sensitivity). Using the presence of one neuron 
with diffuse labelling of the entire cytoplasm (grade 3) in rectal biopsies as the criterion 
for EGS diagnosis yielded a 95% sensitivity and 100% specificity for EGS diagnosis.  
The weighted immunoreactivity grade for EGS samples collected ante-mortem 
(median 2.03; IQR 1.46-2.62) was not significantly different (p=0.089) to that for 
samples collected post-mortem (median 1.58; IQR 1.22-1.84). Further analyses were 
not performed for control samples, as only 2 were collected ante-mortem. The median 
number of total neurons per section was higher in chronic cases (median 60; IQR 27-
69.5) than acute/ subacute cases (median 34; IQR 23-49); however, the difference was 
not significant.  
The median prevalence of grade 3 neurons in EGS horses was 11.4% (Table 2.3). The 
total estimated population of submucosal neurons that could be biopsied within the 
rectum was 23-46,000,000 per horse, depending whether each nucleus was in 1 or 2 
adjacent sections. If the total population of submucosal neurons that could be sampled 
by a rectal biopsy is >5000, grading of at least 30 neurons would be required to have 
96% confidence that a grade 3 neuron was or was not present at the expected median 




Table 2.2: Total number of neurons counted in rectal biopsy sections for individual horses and 
grades of β-amyloid precursor protein immunolabelling (% of total neurons). Data for 
equivocal cases that had overlapping criteria for the diagnosis of a control or equine grass 
sickness case are highlighted in red. 
 





















Control 99.7 0.3 0 0 0 0.003 388
100 0 0 0 0 0.000 380
99.4 0.6 0 0 0 0.006 157
100 0 0 0 0 0.000 341
100 0 0 0 0 0.000 228
98.3 1.7 0 0 0 0.017 59
99.6 0.4 0 0 0 0.004 234
98.9 1.1 0 0 0 0.011 360
100 0 0 0 0 0.000 200
99.6 0.4 0 0 0 0.004 568
98.7 1.3 0 0 0 0.013 308
11.3 71.7 17 0 0 1.057 53
23 74.3 2.7 0 0 0.797 187
99.1 0.9 0 0 0 0.009 111
99.3 0.7 0 0 0 0.007 286
100 0 0 0 0 0.000 121
91.1 8.9 0 0 0 0.089 123
85.4 14.6 0 0 0 0.146 158
76.3 23 0.7 0 0 0.244 139
69.9 29.2 0.9 0 0 0.310 106
100 0 0 0 0 0.000 292
98.4 1.6 0 0 0 0.016 64
98.2 1.8 0 0 0 0.018 57
Acute grass sickness 1.6 16.1 45.2 37.1 23 2.178 62
15.7 37.1 47.2 0 0 1.315 70
4.8 28 41.6 25.6 32 1.880 125
0 0 8.5 91.5 43 2.915 47
9.5 50 32.4 8.1 6 1.391 74
0 5.8 35.5 58.7 71 2.529 121
Sub-acute grass sickness 0 2.1 51.1 46.8 22 2.447 47
0 0 9.6 90.4 113 2.904 125
1.2 42.7 46.3 9.8 8 1.647 82
1.8 84.5 11.9 1.8 2 1.137 110
5 15 70 10 2 1.850 20
0 47.7 27.3 25 11 1.773 44
11.4 27.2 43.2 18.2 8 1.682 44
3.3 36.7 33.3 26.7 16 1.834 60
20.5 54.5 13.6 11.4 5 1.159 44
0 1.2 29.6 69.2 56 2.680 81
0 82.1 14.3 3.6 1 1.215 28
14.3 53.2 28.6 3.9 3 1.221 77
Chronic grass sickness 3.7 37 57.4 1.9 1 1.575 54
17.5 29.1 51.7 1.7 2 1.376 120






Fig 2.6: Percentage distribution of rectal submucosal neuronal grades for individual horses 












             2.7a. 
 
 
              2.7b.  
Fig 2.7: Representative images of β-amyloid precursor protein immunolabelling of rectal 



















































































































































































































































































































































































































































































































































































































































































































































Fig 2.8: Receiver operating characteristic curve for number of grade 3 rectal submucosal 
neurons required for the diagnosis of equine grass sickness. The numbers adjacent the red dots 






2.4.4 Non-neuronal labelling and artefacts 
Intimal asteroid bodies (De Oliveira et al., 1985) were unlabelled in the control 
sections but were immunopositive in other sections (Fig 2.9a). This labelling was 
readily differentiated from positive neuronal labelling because of their location, 
protruding into the lumen of small arterioles and lack of nucleus. Pigment granules 
(haemosiderin and/ or lipofuscin) within macrophages were evident in the submucosa 
of some horses, and could be distinguished from immunolabelling by the 
characteristics of the pigment, presence in corresponding control sections and 
characteristics of cell morphology (Fig 2.9b). Oval particles of plant debris were 
occasionally translocated from the lumen during the biopsy procedure and could 
readily be differentiated by morphological characteristics including the absence of 
nuclei (Fig 2.9c). 
 
  






                                
               
      2.9c.   
Fig 2.9: Examples of non-neuronal labelling and pigment artefacts (a) vascular intimal asteroid 
bodies (bar = 10µm), (b) macrophages containing intracytoplasmic pigment (bar = 10 µm), 




β-amyloid precursor protein immunoreactivity was increased in neuronal perikarya 
and axons in sections of CCG, ileum and rectum from EGS horses compared with 
controls. These data extend previous findings of increased β-APP immunoreactivity in 
CCG sections and increased expression of β-APP in CCG protein extracts in EGS 
(McGorum et al., 2015b).  
β-amyloid precursor protein is synthesised in the endoplasmic reticulum and 
transported through the Golgi apparatus, plasma membrane and axons (Muresan and 
Muresan, 2015). The pattern of labelling observed in control rectal submucosal 
neurons (Fig 2.2: grade 1) is consistent with this normal cellular processing of β-APP, 
and is similar to that observed in other neuronal populations. In contrast, some neurons 
in EGS horses had intense granular to diffuse labelling throughout the cytoplasm (Fig 
2.3b), indicating abnormal accumulation of β-APP; consistent with dysfunction and 
degradation of membrane-bound compartments. This study confirms previous work 
(McGorum et al., 2015b) that EGS is associated with accumulation of β-APP in 
perikarya of degenerate neurons, in adjacent nerve processes and in intra-ganglionic 
axons, but not in larger nerve fascicles. Potentially this may reflect (a) upregulation of 
neuronal synthesis of these proteins, (b) reduced catabolism of β-APP, (c) dysfunction 
of glycoprotein processing in the Golgi network, and/or (d) failure of axonal transport 
of protein-containing vesicles to the nerve terminal. Accumulation of β-APP in the 
perikarya and intra-ganglionic axons, but not in larger nerve fascicles is consistent with 
the latter. Consistent with the latter two hypotheses, ultrastructural loss of a 
recognizable Golgi structure is a likely early event in EGS, and EGS is associated with 
major perturbations in the cytoskeleton of autonomic neurons resulting in 
accumulation of dopamine-β-hydroxylase and presynaptic proteins in neuronal 
perikarya (Scholes, 1991, Griffiths et al., 1993, McGorum et al., 2016b).  
Evaluation of β-APP immunolabelled rectal biopsy sections using a standardised 
grading scheme can aid diagnosis of EGS. Indeed, for the sections evaluated in this 
study, a weighted immunoreactivity grade exceeding 1.1 was 100% specific and 
sensitive for EGS, and the presence of at least one neuron with diffuse labelling of the 
entire cytoplasm (grade 3) was 95% sensitive and 100% specific for EGS. This 
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diagnostic accuracy is comparable to that of conventional histological examination of 
ileal biopsies (Milne et al., 2010, Scholes et al., 1993a) which has a sensitivity and 
specificity of 100% (Milne et al., 2010) and is significantly higher than that of 
conventional histological examination of two rectal biopsies (sensitivity 21%) (Mair 
et al., 2011). However, it should be stressed that further validation of this technique is 
required prior to its application to clinical cases.  
A subset of CCG, ileal and rectal biopsy samples were pre-screened in order to 
establish objective grading schemes and to identify non-neuronal staining, prior to 
blinded evaluation. Individual neuronal perikarya and axons were used as examples of 
β-APP immunolabelled neurons to facilitate development and refinement of the 
grading schemes, with absolutely no bearing on whether the neurons were derived 
from control or EGS sections. The grading scheme was then applied blindly to 
determine which grading parameter had the greatest diagnostic accuracy in 
discriminating EGS and control sections.  
A limitation of the study was that although the diagnostic criteria facilitated 
differentiation of EGS and control samples in this sample set, further development and 
prospective validation of both the grading scheme and the diagnostic criteria using 
larger numbers of EGS and control samples is necessary before the diagnostic value 
of this approach can be fully advocated.  
While most EGS and control samples could be readily differentiated based on the 
intensity and distribution of neuronal β-APP immunoreactivity using the criteria of 
>5% grade 3 neurons (EGS), >40% grade 0 neurons (control) and high proportion of 
grade 2 neurons (EGS), a sub-population of samples (n=9, highlighted in red in Table 
2.2) were considered to be equivocal. Whilst this sub-population would have been 
correctly classified using the criteria of weighted immunoreactivity grade exceeding 
1.1, in a clinical situation, there would be a degree of uncertainty. Consequently, the 
use of these criteria in a clinical situation would have reduced the confidence in a 
diagnosis based solely on this diagnostic approach, a significant consideration in light 
of the fact that a false positive result could prompt euthanasia of a horse without EGS. 
It is important to note however, that these samples would have been highlighted as 
equivocal and not erroneously diagnosed. Further work is therefore required to 
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optimise differentiation of the equivocal sub-population of samples. While a weighted 
immunoreactivity grade exceeding 1.1 was 100% specific and sensitive for EGS, there 
are limitations to the use of this criterion for EGS diagnosis. Firstly, there was very 
little difference between the highest weighted immunoreactivity grade for control 
horses (1.057) and the lowest weighted immunoreactivity grade for EGS horses 
(1.137); consequently, it is possible that this criterion may not be fully discriminatory 
when a larger sample size is prospectively evaluated. Further limitations of this 
criterion are that it is laborious to determine and likely subject to a degree of inter-
observer variability.  
Similarly, while the presence of at least one grade 3 neuron was 95% sensitive and 
100% specific for EGS, use of this criterion is potentially limited by errors in 
differentiating grade 2 and grade 3 neurons. To reduce this error, very objective 
grading criteria were developed and applied, such that grade 3 neurons had diffuse 
labelling of the entire cytoplasm, extending right up to the perikaryonal margin, except 
when this was displaced by cytoplasmic vacuolation (Fig 2.3). This potential limitation 
is confounded by the relative paucity of grade 3 neurons in rectal biopsies of EGS 
cases (median 11.4% of neurons, IQR 2.8-42) compared to CCG (median 35.5, IQR 
21-41). Consequently, EGS diagnosis was based on the presence of only a few grade 
3 neurons, and in occasional cases only 1 grade 3 neuron (n=2 horses). Chromatolytic 
neurons have been reported in the coeliacomesenteric ganglia, jejunum, ileum and 
small colon in clinically normal horses (Doxey et al., 1995b). Whilst the assessment 
of chromatolysis is subjective, and relatively objective immunolabelling grading 
criteria may reduce the likelihood of incorrectly classifying neurons, a larger sample 
size is required to determine if grade 3 neurons are ever present in control horses. 
Although increasing the threshold for the diagnosis of EGS to the presence of ≥4 grade 
3 neurons would increase the diagnostic certainty, it would also reduce the sensitivity 
to 62% (Fig 2.8).  
Many CCG, ileal and rectal neurons from EGS horses, but not control horses, had 
pyknotic nuclei (Fig 2.3c). Further study is required to determine whether this 
conventional histopathological analysis for morphologic features of 
neurodegeneration, together with chromatolysis and neuronal swelling, could be 
incorporated into the grading scheme to improve diagnostic accuracy of rectal 
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biopsies. The assessment of inter- and intra-grader correlation is warranted to 
determine the repeatability of the proposed grading scheme.  
Further work is required to assess the effect of EGS sub-classification on neuronal β-
APP immunoreactivity. Consistent with previous work (Scholes et al., 1993b, Doxey 
et al., 1992), a higher proportion of normal neurons was found in chronic cases; all 3 
CGS sections had significantly fewer grade 3 rectal neurons than acute and subacute 
cases. Consistent with a further study (Doxey et al., 1995b), the median number of 
total neurons per section was higher in chronic cases than acute/ subacute cases; 
however the difference was not statistically significant and data from more chronic 
cases should be assessed to further investigate these findings. Acute and subacute 
forms of the disease are invariably fatal, while some cases of CGS survive with 
appropriate nursing (Milne et al., 1994, Doxey et al., 1995a, Doxey et al., 1998, Doxey 
et al., 1999, Jago et al., 2015). A larger data set of chronic cases is required to 
investigate the potential prognostic value of β-APP immunolabelling.  
Whilst estimations indicate that at least 30 neurons must be examined to be 96% 
confident that a grade 3 neuron was or was not present, at the expected median 
prevalence of 11.4%, it is likely that the diagnostic value of rectal biopsies could be 
improved by increasing the number of biopsies collected from each horse, and by 
examining multiple non-serial sections cut from individual biopsies. Previous studies 
indicate that the density of submucosal neurons does not have a consistent 
circumferential pattern in rectal samples (Wales and Whitwell, 2006), indicating that 
collection of biopsies from specific locations around the circumference of the rectal 
wall cannot reliably maximise the number of neurons sampled. While the total number 
of neurons identified in control rectal biopsies exceeded that of EGS biopsies, this 
reflected the increased number of biopsies collected from controls. Consequently, 
there was no intergroup difference in the median number of neurons per section. The 
median number of rectal biopsies collected for EGS horses was comparable to the 
previous study by Mair et al. (2011). More biopsies were collected from control horses 
to increase the confidence of the calculated specificities.  
The effect of ante-mortem versus post-mortem sampling must be further evaluated. 
Both control samples that were collected ante-mortem had lower percentages of grade 
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0 neurons and were the only control cases that were classified as equivocal. Whilst 
there was a difference of 0.45 between the median weighted immunoreactivity grades 
of EGS samples collected ante- and post-mortem, the difference was not significant. 
The use of relatively non-invasive rectal biopsies versus ileal biopsies collected at 
laparotomy to diagnose EGS offers economic, welfare and time benefits. A 
disadvantage is the increased time required for immunolabelling of rectal biopsies 
compared with H&E staining of ileal biopsies; total sample fixing and processing times 
being, respectively, a minimum of 12h and 6h. The timescale may be appropriate for 
ante-mortem diagnosis of subacute and CGS cases and post-mortem confirmation of 
EGS in horses that are subjected to euthanasia in the field when the invasive removal 
of CCG or ileum is not feasible. However, this technique may be unsuitable for rapid 
ante-mortem diagnosis of acute EGS, unless the time requirement can be reduced, 
perhaps by using accelerated fixation protocols, frozen sections and employing rapid 
immunolabelling techniques.  
In conclusion, this work has demonstrated the potential diagnostic value of 
immunolabelled rectal biopsies for EGS diagnosis. However, further prospective 
studies are required before the use of this technique can be fully advocated in clinical 
decision making.  
 
2.6 Manufacturers’ addresses 
aEquivet uterine biopsy forceps; Kruuse UK Ltd, Sherburn in Elmet, UK 
bDakoCytomation EnVision+ System-HRP; DAB K4001; Dako, Ely, UK 
cDako Real Peroxidase Blocker S2023; Dako, Ely, UK 
dMAB, clone 22C11, mouse anti-alzheimer precursor protein A4 antibody; Millipore, 
Watford, UK 
eLiquid DAB; ImmPact Dab SK4105; Vector Laboratories, Peterborough, UK 
fhttp://epitools.ausvet.com.au  




3 Chapter Three: Bodyweight change aids prediction 
of survival in chronic equine grass sickness 
 
3.1 Hypothesis 
This study tested the hypothesis that magnitude and/ or rate of bodyweight change 
from first weighing could provide an objective predictor of outcome in CGS cases, 
with the magnitude and rapidity of bodyweight loss being less in survivors (S).  
 
3.2 Materials and methods  
3.2.1 Study design and data collection  
A single centre retrospective observational study was conducted. Records of all horses 
admitted for management of CGS to The Dick Vet Equine Hospital between 1998 and 
2013, inclusive, were analysed. Information obtained from records included age 
(years), gender (female/ entire male/ gelding), breed, survival to hospital discharge; 
hereafter referred to as survival status (S/ non-survivors (NS)), duration of disease at 
admission (days) as reported by the owner, duration of hospitalisation (days), body 
weights (kg), and indication(s) for euthanasia that were recorded in the final clinical 
report. Survival was defined as discharge from the hospital. Horses were excluded if 
they met the following case exclusion criteria: <2 weights were recorded or 
exploratory laparotomy was performed. Body weights were determined using a 
weighbridgea at variable times throughout the hospitalisation period.    
3.2.2 Patient management 
Horses were nursed according to published guidelines (McGorum et al., 2009), 
consisting predominantly of offering a variety of highly palatable concentrate feeds of 
varying consistencies. Initially cases were fed every 2 h, with the frequency reducing 
as the volume of feed tolerated increased. Horses were walked daily or turned out to 
grass, provided this would not compromise their weakness. Analgesics and hyoscine 
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were administered as required for episodes of colic. Some horses also received 
omeprazole, NSAIDs, antimicrobials, sedatives, diazepam, brotizolam, aloe vera, 
probiotics, dexamethasone, cisapride, and acetylcysteine. Continuous flow enteral 
feeding and total or partial parenteral nutrition were used in a few selected cases. 
3.2.3 Data analysis 
Data were entered into an Excel spreadsheet. Categorical variables were described as 
percentages and chi-squared tests were used to investigate the association between 
categorical variables and survival status. As the continuous variables were not 
normally distributed, they were summarised using medians and IQR. Mann-Whitney 
U tests were used to investigate their association with survival. Age was analysed as 
both a continuous and a categorical variable (using categories 1-2, 3, 4, 5, 6, 7, 8, 9-10 
and ≥11 years).  
Summary statistics were calculated for each horse including minimum weight (as a 
percentage of first weight recorded), time from first weight recorded to minimum 
weight, duration of disease on admission and duration of hospitalisation. These were 
compared between survival status groups using Mann-Whitney U tests. Kaplan-Meier 
survival and time to discharge curves, from reported onset of disease, were constructed 
for NS and S, respectively. Individual horse’s bodyweights were plotted temporally, 
as a percentage of the first recorded weight, comparing S and NS.  
Referenced to day of first weight recorded, percentage bodyweight changes for each 7 
day interval up to 28 days (0-7, 7-14, 14-21, 21-28 days) were used to describe the 
rapidity of weight loss. Percentage bodyweight changes over entire periods from the 
first weight (0-7, 0-14, 0-21, 0-28 days) were used to describe the overall magnitude 
of weight loss. If weight data were not available for the start or end of a 7-day interval, 
linear interpolation of the weights before and after were used to generate an estimate.  
Histograms were constructed from these derived data. 
The percentage weight changes for all intervals for S and NS were described, and 
compared using Mann-Whitney U tests. The predictive value of data from each time 
period for identifying NS was described using ROC curves including estimation of 
AUC.  An optimal cut-off was also proposed by identifying a point that would give 
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maximum sensitivity with an estimated specificity of 1.0. A specificity of 1.0 was 
selected (i.e. no false positives within the study data), to minimise the possibility that 
a potential S would be euthanised inappropriately. Estimated sensitivity was reported 
together with estimated 95% confidence intervals for sensitivity based on 2000 
bootstrap replications of ROC curves.  
As a potential clinical discussion tool the percentage weight changes for horses over 
each interval and period were summarised to estimate the probability of survival of 
horses grouped into ranges of percentage weight change (percentage survival 
prediction curves). As these estimates were based on low numbers of individual horses, 
the uncertainty in the estimates was expressed with binomial exact confidence 
intervals. 
As bodyweights were only recorded during the hospitalisation period and few horses 
were admitted on the day of onset of clinical signs, weight data were generally not 
available from the day of disease onset. To determine if correcting for this delay would 
improve predictive performance, extrapolations were performed to estimate the weight 
on the day of disease onset i.e. the first day that owners recognised abnormal clinical 
signs. The extrapolation to day of onset used a quadratic model fitted to each horse’s 
first 6 recorded weights, only when a weight was available ≤7 days after the onset of 
clinical signs, and where ≥6 weights had been recorded. These inclusion criteria for 
extrapolation were selected on iterative examination of fitted values under different 
criteria and discussion with experienced clinicians blind to the outcome of the 
individual horse. An extrapolated onset weight was not calculated for horses outside 
these criteria. Histograms and the associated quantitative data were produced for both 
extrapolated data (day 0 = day of disease onset) and non-extrapolated data (day 0 = 
day of first recorded weight) for all time intervals.  
The R statistical systemb was used for all statistical analyses. P<0.05 was used as the 
threshold for statistical significance. This study conformed to Standards for the 






Since 28 of the 241 horses hospitalised for management of CGS met the case exclusion 
criteria, the study sample comprised 213 horses. Median age was 5 years (IQR 3.5-8). 
There were 96 (45.1%) females, 104 (48.8%) geldings and 13 (6.1%) entire males. 
Breed categories consisted of 22 (10.3%) Scottish native ponies, 31 (14.6%) other 
ponies, 19 (8.9%) Thoroughbreds, 42 (19.7%) cobs, 17 (8%) draft horses, 11 (5.2%) 
warmbloods, 13 (6.1%) other pure breeds and 58 (27.2%) crossbreeds. No signalment 
variables were associated with increased risk of non-survival.  
There were 114 (53.5%) S and 99 (46.5%) NS. The survival rate was (53.5%) for the 
213 horses included in the study, and 49.4% for all (241) horses hospitalised for 
management of CGS during the study period. All NS were euthanised, with none 
dying. For 92 of the 99 NS, information was available describing the indications of 
euthanasia. The most prevalent (29.3% of NS) single indication for euthanasia was 
recumbency and inability to stand. Seven cases were euthanised for other single 
indications including aspiration pneumonia, functional post-renal obstruction, 
cardiovascular collapse, diarrhoea, persistent anorexia and recurrent colic. Fifty eight 
horses (63.1%) were euthanised for multiple indications (Table 3.1). Although weight 
loss was the most prevalent indication when multiple indications for euthanasia were 















(of 58 horses) 
Weight loss 28 48.3 
Anorexia 24 41.4 
Progressive weakness 21 36.2 
Dysphagia  20 34.5 
Deteriorating demeanour 19 32.8 
Rhinitis sicca 19 32.8 
Deteriorating appetite 16 27.6 
Recurrent colic 10 17.2 
Diarrhoea 8 13.8 
Other 6 10.3 
Acute severe colic  5 8.6 
Recumbent and unable to stand ( + assistance) 2 3.4 
Gastric reflux  2 3.4 
Functional post-renal obstruction 2 3.4 
Aspiration pneumonia  2 3.4 
Persistent tachycardia  2 3.4 
Table 3.1: Frequency of reported indications for euthanasia in 58 horses that had >1 indication 
for euthanasia.   
There was no significant difference in age of S (median 5 years, IQR 3-8) and NS (5 
years, 4-8), nor in duration of disease prior to hospitalisation (S 6 days, IQR 2-10; NS 
5, 2-8). Survivors were hospitalised for significantly longer than NS (S 34 days, IQR 
22-60; NS 14, 10-25; p<0.00001) (Fig 3.1). Kaplan-Meier survival curve indicated that 
50% of NS were euthanised by 21 days and 75% by 32 days from onset of disease (Fig 
3.1a). A time to discharge curve for S indicates that 50% were discharged by day 42 
from onset of disease (Fig 3.1b). 
Horses were weighed on average every 2 days (IQR 1-3); the frequency was not 
significantly different between S and NS. Compared with NS, S had significantly 
lower maximum bodyweight loss as percentage of first weight (S 5.9%, IQR 1.8-13.5; 
NS 12.7, 6.4-17.3; p<0.0001), and a significantly earlier day of minimum weight (S 
day 17, 13-27; NS 23, 17-33; p=0.0008). All NS lost weight, whereas some (45.6%) S 
gained weight or shortly reached their nadir and then rapidly increased, making the 
overall gradient of the curve less in S (Fig 3.2). The highest percent of total bodyweight 
loss by individual S and NS was similar (36% and 37%, respectively).  
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Using overall magnitude and rapidity of bodyweight change data referenced to first 
weight, S had significantly lower weight loss than NS at all periods listed in Table 3.2. 
The greatest percentage of bodyweight loss within a 7 day period occurred between 0 
and 7 days, for both S and NS. The AUC was similar for all time periods, but highest 
between 14 and 21 days. When the cut-off was set to give a specificity of 1.0, 
sensitivity was fairly low for all time periods, but was greatest for the 7 to 14 day 
interval (Table 3.2).  
The percentage bodyweight change of S and NS from day 0 (first weight) to 7 is 
presented in Fig 3.3, with histograms for other time intervals being presented in Fig 




Fig 3.3: Histogram demonstrating the percentage bodyweight change of survivors (S) and 
non-survivors (NS) from day 0 (1st weight) to day 7. For example, 13 horses lost 2% 
bodyweight and all these were S. Six horses lost 12% bodyweight and all were NS. Thirty 





Fig 3.4: Histograms demonstrating the percentage bodyweight change of survivors and non-
survivors for each 7 day period and each period from the time of first weight up to 28 days, 















































































































All the aforementioned results reported and later discussed are based on non-
extrapolated data, with day 0 as the first weight recorded. Only 93 horses met the 
criteria for extrapolation to estimate a weight at onset of disease. The predictive 
performance measures based on extrapolated weights were overall less informative 
than the measures based on first weight recorded (AUC lower for 7/8 models based on 
extrapolated weight compared to first weight). As extrapolation only estimates the 
weight at onset, it is possible that the standardising of timing it adds is overwhelmed 
by the error introduced by the quadratic model extrapolation. 
 
3.4 Discussion  
This is the largest study to report the outcome of hospitalised CGS cases (Milne et al., 
1994, Doxey et al., 1995a, Doxey et al., 1998, Doxey et al., 1999). The survival rates 
of 49.4% for all (241) horses hospitalised for management of CGS during the study 
period, and of 53.5% for the 213 horses included in the study, were higher than 
previously reported (35.6% (Milne et al., 1994) and 42.7% (Doxey et al., 1995a)). The 
difference in percentage survival of all 241 horses compared with the 213 horses used 
in the study reflects the higher number of NS in the excluded sample (23/28), likely 
because some were euthanised soon after admission, prior to recording the >2 weights 
required for study inclusion.  
For any given change in percentage bodyweight over any of the defined time intervals 
the percentage survival prediction curves report the survival rate in our study sample 
gathered over the last 16 years. These curves can be used to predict the survival of 
future cases. Obviously each clinical case should be assessed on a case by case basis, 
for example if the horse has concurrent aspiration pneumonia or colic, or is one of the 
outliers, but these values can be used as a prognostic discussion aid derived from 
previous outcomes, to help guide owner decisions. For example, if a horse had lost 5% 
bodyweight after 21days and the owner was considering euthanasia, our data indicate 
that 100% of horses losing this amount of weight over this time period previously 
survived to discharge.  
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Compared with NS, S had significantly lower median maximum bodyweight loss 
overall and for each individual time period analysed. The greatest difference in median 
weight loss of S and NS occurred between days 14 and 21. The greatest AUC was also 
for this time period, however the confidence intervals of all areas overlap, so we cannot 
report that this value is significantly greater. Whilst the AUC is an objective measure 
of overall discrimination, both this and the difference between the medians is a 
population statistic and is not indicative of the best diagnostic predictor for 
discriminating S from NS on an individual basis. With a guaranteed specificity of 1.0, 
the highest achievable sensitivity was 0.22 for the 7 to 14 day time interval. However, 
the value 0.22 is not significantly greater than other intervals due to the low sample 
sizes in each group. In conclusion, we were unable to definitively select a single 7 day 
interval of time over another as the best discriminator between S and NS. As weight 
loss data from longer intervals (0-14, 0-21 etc.) did not provide more predictive data 
than from 7 day periods, the latter are preferred because they are practically easier to 
obtain.  
Data from the Kaplan-Meier survival curve aided the selection of periods of time to 
analyse the changes in bodyweight. Since only 29.3% of NS survived beyond 28 days, 
data for subsequent time periods (> 28 days) were less predictive. Furthermore, factors 
other than weight loss appeared to contribute to non-survival in horses beyond 28 days, 
explaining the outlying cases for NS evident in Fig 3.2. For example the horse 
euthanised after 4 months had reached its nadir and started to increase weight but was 
subsequently euthanised for acute onset intestinal ileus.  
The median maximum percentage weight loss for S from first weighing was similar to 
that previously reported (5.2% for 34 horses; (Doxey et al., 1995a)). Clearly these data 
underestimate the actual weight loss occurring from disease onset. We would have 
hypothesised that horses lose the greatest percentage of bodyweight within the first 
week because of the initial reduction in mass of gastrointestinal contents. The greatest 
percentage total bodyweight loss for individual horses was comparable for S and NS, 
demonstrating that S can survive despite losing significant weight. This emphasises 




The median age of all horses in this study is consistent with previous reports regarding 
EGS (Doxey et al., 1991a, McCarthy et al., 2004). Unlike Milne et al. (1994) who 
found ponies significantly less likely to survive than cobs and Doxey et al. (1998) who 
found cobs and Thoroughbreds overrepresented in S, no breeds in the present study 
were associated with an increased risk of non-survival.  
The duration of hospitalisation for S (34 days) was comparable for horses treated 
between 1991 and 1994 (median 31 days) (Doxey et al., 1995a). Horses were typically 
discharged from the hospital when they were consistently gaining weight whilst 
receiving feeds at a frequency that the owners could continue to feed at home. 
Obviously this is dependent on owners’ willingness or desire to have the patient home 
before recovery is fully established. Few cases had returned to their original weight at 
the time of discharge. Doxey et al. (1999) did not find any correlation between duration 
of hospitalisation and subsequent quality of life of patients.  
It is important to note that horses were never euthanised solely because of weight loss. 
The most prevalent single reason for euthanasia was recumbency and inability to stand 
due to skeletal muscle weakness. The pathogenesis of muscle weakness in CGS is 
unclear, but likely reflects muscle catabolism subsequent to cachexia and possibly 
neurogenic motor weakness (Hahn et al., 2001). It is unsurprising that weight loss was 
reported as the most prevalent indication when multiple indications for euthanasia 
were reported.  
Currently, the diagnosis of grass sickness can only be definitively confirmed by 
histopathology of autonomic ganglia at post mortem or biopsies of the enteric nervous 
system collected at exploratory laparotomy (Scholes et al., 1993a, Milne et al., 2010). 
In the present study CGS was presumptively diagnosed after considering the nature 
and progression of clinical signs, history, signalment, epidemiological factors, and 
elimination of alternative diagnoses (Pirie et al., 2014). Diagnosing CGS by clinical 
examination, by clinicians familiar with the disease, has a reported accuracy of 100% 
(Doxey et al., 1998). Consistent with these data, all 79 NS that had a post mortem 
examination including histopathological examination of neural tissue were confirmed 
to have CGS. Consequently, we consider that diagnostic errors were unlikely to have 
influenced the conclusions of this study.  
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Survival was defined as discharge from the hospital. Whilst long-term follow up of 
cases was not done, previous studies indicate that the majority of CGS horses return 
to full athletic function (Doxey et al., 1995a, Doxey et al., 1998, Doxey et al., 1999). 
Doxey et al. (1995a) reported that 4 of 35 CGS cases were euthanised or died 
subsequent to hospital discharge.  
The pathogenesis of weight loss in EGS is incompletely understood but is likely 
multifactorial, reflecting some of the following; lack of food intake, increased 
metabolic rate, cachexia, and neurogenic muscle atrophy. The authors are unaware of 
studies reporting the magnitude of weight loss sustained in horses following simple 
starvation, which could have been used to determine if weight loss is largely a 
consequence of reduced feed intake or if cachexia is a contributing factor. Horses 
experimentally deprived of food and water for 7 days had a 10% (range 8.2-10.3%) 
median body weight loss (Tasker, 1967). In the present study, 23% of horses lost ≥10% 
bodyweight over the first 7 days from the first recorded weight, suggesting that 
mechanisms other than simple starvation, such as cachexia, contributed to weight loss. 
Furthermore, since CGS cases were drinking and not completely anorexic, the weight 
loss would be expected to be less than reported with complete food and water 
deprivation. Cachexia is distinct from simple starvation, being defined as a complex 
metabolic syndrome associated with underlying disease and characterised by loss of 
muscle (Evans et al., 2008). Consistent with involvement of cachexia in grass sickness, 
affected horses have amino acid perturbations that resemble severe protein 
malnutrition, consistent with cachexia, and differing from simple starvation 
(McGorum and Kirk, 2001). Weight loss is a powerful independent variable that 
predicts mortality in human patients with cancer (Viganò et al., 2000), HIV (Wheeler 
et al., 1998) and the elderly in nursing homes (Sullivan et al., 2004). Excessive 
elaboration of proinflammatory cytokines such as interleukin (IL) 1, IL6 and tumour 
necrosis factor α is reported as the most common cause of cachexia in acutely ill human 
patients (Kotler, 2000). Proinflammatory cytokines signal an increase in the synthesis 
of acute phase proteins by hepatocytes. Increases in acute phase proteins such as 
fibrinogen, serum amyloid A (Copas et al., 2013) and haptoglobin (Milne et al., 1991) 
have been reported in EGS, suggesting activation of the entire inflammatory cascade 
and may provide further evidence that CGS horses are cachectic.  
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Potential errors in the data for duration of disease upon hospital admission, obtained 
from owners, may have resulted from delayed recognition of the subtle early signs of 
CGS particularly in horses at pasture. Greater sample sizes within the individual time 
intervals would be required for greater sensitivity and associated confidence intervals. 
Despite a relatively high prevalence of the disease in this area (Wylie and Proudman, 
2009, Wylie et al., 2011), a significant extension in the time period for which the data 
was collected would be required for greater sample sizes. The percentage survival 
prediction curves could be used prospectively to determine their accuracy. The 
percentage survival prediction curves are applicable to our study population, and are 
likely to be less applicable to horses that do not receive intensive nursing care.  
The recorded bodyweights in the study were obtained with an accurate weighbridge. 
To allow practitioners and owners in an ambulatory setting to use the percentage 
survival predictive curves, we performed a pilot study to determine which weigh tape 
measurement method would most accurately estimate the bodyweight (Appendix 1). 
In conclusion, NS had greater bodyweight loss than S. Rapidity and magnitude of 
bodyweight loss were equally predictive of outcome. Percentage survival prediction 
curves provide objective data to aid discussion of prognosis, but greater predictive 
specificity with associated sensitivity is required for clinical decision making for 
individual horses. 
 
3.5 Manufacturers’ addresses 








4 Chapter Four: Conclusions  
4.1  Study to increase the accuracy of equine grass sickness diagnosis 
using β-amyloid precursor protein immunolabelled rectal biopsies 
 β-amyloid precursor protein immunoreactivity was increased in neuronal 
perikarya and axons in sections of CCG, ileum and rectum from EGS horses 
compared with controls. 
 The best diagnostic predictors for discriminating EGS and control horses for 
the sections evaluated in this study were a weighted immunoreactivity grade 
exceeding 1.1, with 100% specificity and sensitivity for EGS, and the presence 
of at least one neuron with diffuse labelling of the entire cytoplasm (grade 3), 
with 95% sensitivity and 100% specificity for EGS.  
 The hypothesis for the first part of the study was accepted, i.e. that 
immunolabelling with β-APP improved the accuracy of histological 
assessment of submucosal rectal biopsies for EGS diagnosis. The diagnostic 
accuracy is comparable to that of conventional histological examination of 
H&E stained ileal biopsies (Milne et al., 2010, Scholes et al., 1993a) and is 
significantly higher than that of conventional histological examination of two 
H&E stained rectal biopsies (Mair et al., 2011).  
 This technique may potentially provide an accurate, minimally invasive, ante-
mortem, diagnostic test for EGS. However, it should be stressed that further 
prospective validation of this technique is required before the use of this 
technique can be fully advocated for clinical decision making.  
4.2  Study to increase the accuracy of prognostication for chronic grass 
sickness 
 Consistent with the hypothesis, NS had greater bodyweight loss than S, for all 
time periods analysed and for the total median maximum bodyweight loss as a 
percentage of first weight.  




 The greatest percentage total bodyweight loss for individual CGS horses was 
comparable for S and NS. This demonstrates that S can survive despite marked 
weight loss, emphasising our recommendation that CGS horses should not be 
euthanised solely based on marked weight loss. 
 Percentage survival prediction curves provide objective data, from previous 
outcomes, to aid discussion of prognosis for CGS horses, but greater predictive 
specificity and sensitivity is required for clinical decision making in individual 
cases. 
In summary, the global aim of increasing the accuracy of diagnosis and 
prognostication for EGS has been achieved. Histological assessment of β-APP 
immunolabelled rectal biopsies aids diagnosis of EGS and bodyweight change aids 













5 Chapter Five: Future research   
5.1  Study to increase the accuracy of equine grass sickness diagnosis 
using β-amyloid precursor protein immunolabelled rectal biopsies 
 While the diagnostic criteria facilitated discrimination of the EGS and control 
rectal biopsies evaluated in this study, further prospective validation of both 
the grading scheme and the diagnostic criteria using a larger sample set is 
required. 
 Further work is required to optimise differentiation of the equivocal sub-
population of samples, perhaps refining the diagnostic criteria with inclusion 
of morphological features of neurodegeneration. 
 Assessment of inter- and intra-grader correlation is warranted to determine the 
repeatability of the proposed grading scheme. 
 A larger sample size is required to determine the effect of EGS sub-
classification on neuronal β-APP immunoreactivity and its potential value for 
prognostication of chronic EGS cases.  
 Greater numbers of pre-mortem samples should be assessed to ascertain the 
possible effect of pre-mortem sample collection on neuronal β-APP 
immunoreactivity. 
 Further investigation of accelerated fixation protocols, frozen sections and 
rapid immunolabelling techniques is required to reduce the time requirement 
for sample processing thereby improving the potential use for diagnosis of 
acute EGS.  
5.2.  Study to increase the accuracy of prognostication for chronic grass 
sickness 
 The percentage survival prediction curves should be tested prospectively to 
determine their accuracy. This should be done blindly after it has been 
determined whether the horse survives to hospital discharge or not, to avoid 
introduction of bias due to use of the percentage survival prediction curves for 
clinical decision making. For example, if a horse had lost a percentage of 
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bodyweight which predicts only 5% survival to discharge, this knowledge may 
bias the clinical decision making process towards euthanasia.  
 Greater sample sizes are required for each individual time interval, to improve 
sensitivity and confidence intervals.  
 A greater sample size of horses weighed using both weigh tapes and weigh 
scales is required before survival prediction curves are used with  data obtained 
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Validation of weigh tape calculations for the 
measurement of bodyweight in chronic equine grass 
sickness cases 
Introduction  
The recorded bodyweights in the study were obtained with an accurate weighbridgea. 
To allow practitioners and owners in an ambulatory setting to use the percentage 
survival predictive curves, we sought to validate and/ or calibrate the data for use with 
a weigh tape. Standard equine weigh tapes rely on girth measurements. However 
horses with chronic grass sickness (CGS) have an initial reduction in volume of 
gastrointestinal contents and a consequent reduction in their abdominal silhouettes, 
and as such it may be necessary to use different anatomical locations for weigh tape 
assessments of body weight in these patients.  
Materials and methods 
Horses admitted to the Dick Vet Equine Hospital between August 2008 and August 
2010 were included in this subsidiary study. Horses were weighed on a weighbridgea 
and simultaneous bodyweights were calculated using 3 different adapted weigh tape 
methods; namely girth A, girth B and abdominal (Table 1). Measurements were 
performed at the same time each day.  
Data analysis  
The percentage bodyweight change over the first 7 days (from first recorded weight) 
was calculated and the discrepancy was plotted for each individual horse for each 
weigh tape method against the true weighbridge value. Bias (mean error), standard 
deviation and root-mean-squared error (RMSE) were calculated for each weigh tape 






 Bodyweight calculation (kg)  
Girth A     G2 x L       
  11,877 
(Carroll et al., 
1988) 
Girth B  -421.563 + (G x 4.737) (Marante et al., 
2007) 
Abdominal -528.096 + (G x 3.101) + (U x 2.266) (Marante et al., 
2007) 
 
Table 1. Bodyweight calculations for the 3 weigh tape methods                                                                     
G = Girth (cm), measured by passing the weigh tape around the thorax immediately caudal to 
the elbow, and recording at the end of expiration.  
L = Length (cm), measured from the point of the shoulder to the tuber ischium, following the 
contours of the horse’s body.  
U = Umbilical girth (cm), measured by passing the weigh tape around the widest aspect of the 
horse’s abdomen, and recording at the end of expiration.  
 
Results 
The subsidiary study sample comprised 11 horses, with 4 survivors and 7 non-
survivors. Median age was 5 years (interquartile range 3-10). There were 6 (54.5%) 
females and 5 (45.5%) geldings.  







1.16 3.68 3.70 
Girth B  
-0.48 3.05 2.95 
Abdominal  
0.74 4.99 4.82 
 
Table 2. Mean error, standard deviation and root-mean-squared error (RMSE) for the 3 
different weigh tape measurements in comparison to the weighbridge measurement, for the 
percentage bodyweight change over the first 7 days from the first weight recorded.  
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The girth B calculation provided the best estimate of the weighbridge bodyweight with 
the smallest mean error, standard deviation and RMSE. This calculation 
underestimated the percentage bodyweight loss over the first 7 days by an average of 
0.48%. The girth A calculation was a poorer estimator; overestimating the percentage 
bodyweight loss by an average of 1.16%. Stratifying by survival status did not provide 
a better estimate.  
Discussion  
For each weigh tape calculation some individual horse’s bodyweights were 
underestimated and some were overestimated in comparison to the weighbridge 
derived weight. Consequently, a simple correction factor could not be utilised to 
correct for the errors in weigh tape measurements. The method most closely estimating 
the weighbridge weight was girth B. Whilst the mean error for the girth B calculation 
was small (0.48%), the standard deviation was wide, and overestimating a horse’s 
percentage bodyweight loss over the first 7 days from the first weight by e.g. 3% could 
change the horse’s survival prediction by 18.75%.  
Horses with CGS develop a characteristic ‘tucked up’ abdominal silhouette and 
considering the gut fill of a horse is 13.5 + 4% of bodyweight (Meyer et al., 1996) it 
is surprising that the abdominal weigh tape calculation did not provide the best 
estimate of weighbridge weight.  
Only 11 horses were included in this subsidiary study and a greater sample size is 
required to confirm these results before the survival prediction curves are used with 
weigh tape bodyweights.  
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Summary
Reasons for performing study: Objective criteria for predicting survival of chronic grass sickness cases are currently lacking.
Objectives: To determine whether the rate and/or magnitude of bodyweight change during hospitalisation of chronic grass sickness cases can provide
an objective predictor of survival to discharge from hospital. Clinicians’ recorded indication(s) for euthanasia were also reviewed.
Study design: Single centre retrospective observational study.
Methods: Case records of all horses admitted for management of chronic grass sickness to The Dick Vet Equine Hospital between 1998 and 2013 were
analysed. Case background, survival to hospital discharge, indication(s) for euthanasia, disease duration at admission and bodyweight changes during
the hospitalisation period were analysed, and data for survivors and nonsurvivors compared. Percentage weight change was calculated for 7 day
intervals up to 28 days (0–7, 7–14, 14–21, 21–28 days) and for entire periods from the first weight recorded (0–7, 0–14, 0–21, 0–28 days). These results
were used to estimate survival probability conditional on weight change.
Results: The study sample comprised 213 horses, with 114 survivors (53.5%) and 99 (46.5%) nonsurvivors. Compared with nonsurvivors, survivors had
significantly lower median maximum bodyweight loss as a percentage of first weight (survivors 5.9%, interquartile range 1.8–13.5; nonsurvivors 12.7%,
6.4–17.3). Throughout all time periods analysed, survivors had significantly lower median bodyweight loss than nonsurvivors, but no specific time
period was more predictive of survival. Highest percentages of total bodyweight loss for individual horses were comparable for survivors (36%) and
nonsurvivors (37%). Survival prediction curves reporting percentage survival rates for all time periods analysed provided data to aid prediction of
chronic grass sickness survival.
Conclusions: Overall, nonsurvivors had greater bodyweight loss than survivors. Rapidity and magnitude of bodyweight loss were equally predictive of
outcome. Percentage survival prediction curves provide objective data to aid discussion of prognosis, but greater predictive specificity with associated
sensitivity is required for clinical decision making in individual cases.
Keywords: horse; grass sickness; dysautonomia; weight loss; cachexia
Introduction
While acute and subacute grass sickness are invariably fatal, some
chronic grass sickness cases survive [1–4]. Currently there are no
objective criteria for predicting the outcome of chronic grass sickness
cases. Accurate prediction of outcome would have welfare and
economic benefits because it could reduce the number of potential
survivors subjected to euthanasia and the number of nonsurvivors that
are given unsuccessful intensive nursing prior to euthanasia. While a
previous study demonstrated that nonsurvival was associated with
severe rhinitis sicca and high subjective clinical scores based on the
severity of dysphagia, anorexia, colic and reduction in intestinal sounds
[1], these indices are fairly subjective. Bodyweight loss, potentially
resulting from anorexia, dysphagia, rhinitis sicca, loss of taste sensation
and cachexia, is a prominent feature of chronic grass sickness [5–7].
This study tested the hypothesis that magnitude and/or rate of
bodyweight change from first weighing could provide an objective
predictor of outcome in chronic grass sickness cases, with the
magnitude and rapidity of bodyweight loss being less in survivors.
Materials and methods
Study design and data collection
A single centre retrospective observational study was conducted. Records
of all horses admitted for management of chronic grass sickness to The
Dick Vet Equine Hospital between 1998 and 2013, inclusive, were analysed.
Information obtained from records included: age (years); sex (female/entire
male/gelding); breed; survival to hospital discharge (hereafter referred to as
survival status: survivor/nonsurvivor); duration of disease at admission
(days) as reported by the owner; duration of hospitalisation (days);
bodyweight (kg); and indication(s) for euthanasia as recorded in the final
clinical report. Survival was defined as discharge from the hospital. Horses
were excluded if they met the following case exclusion criteria: <2 weights
were recorded or exploratory laparotomy was performed. Bodyweights
were determined using a weighbridgea at variable times throughout the
hospitalisation period.
Case management
Horses were nursed according to published guidelines [8], consisting
predominantly of offering a variety of highly palatable concentrate feeds of
varying consistencies. Initially, cases were fed every 2 h, with the
frequency reducing as the volume of feed tolerated increased. Horses
were walked daily or turned out to grass, provided this would not
compromise their weakness. Analgesics and hyoscine were administered
as required for episodes of colic. Some horses also received omeprazole,
nonsteroidal anti-inflammatory drugs, antimicrobials, sedatives, diazepam,
brotizolam, aloe vera, probiotics, dexamethasone, cisapride or
acetylcysteine. Continuous flow enteral feeding and total or partial
parenteral nutrition were used in a few selected cases.
Data analysis
Data were entered into an Excel spreadsheet. Categorical variables were
described as percentages and chi-squared tests were used to investigate
the association between categorical variables and survival status. As the
continuous variables were not normally distributed they were summarised
using medians and interquartile ranges (IQR). Mann–Whitney U tests were
used to investigate their association with survival. Age was analysed as
both a continuous and a categorical variable (using categories 1–2, 3, 4, 5,
6, 7, 8, 9–10 and ≥11 years).
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Summary statistics were calculated for each horse, including minimum
weight (as a percentage of first weight recorded), time from first weight
recorded to minimum weight, duration of disease on admission and
duration of hospitalisation. These were compared between survival status
groups using Mann–Whitney U tests. Kaplan–Meier survival and time to
discharge curves, from reported onset of disease, were constructed for
nonsurvivors and survivors, respectively. Individual horse’s bodyweights
were plotted temporally, as a percentage of the first recorded weight,
comparing survivors and nonsurvivors.
Referenced to day of first weight recorded, percentage bodyweight
changes for each 7 day interval up to 28 days (0–7, 7–14, 14–21,
21–28 days) were used to describe the rapidity of weight loss. Percentage
bodyweight changes over entire periods from the first weight (0–7, 0–14,
0–21, 0–28 days) were used to describe the overall magnitude of weight
loss. If weight data were not available for the start or end of a 7-day
interval, linear interpolation of the weights before and after were used to
generate an estimate. Histograms were constructed from these derived
data.
The percentage weight changes for all intervals for survivors and
nonsurvivors were described, and compared using Mann–Whitney U tests.
The predictive value of data from each time period for identifying
nonsurvivors was described using receiver operating characteristic curves
including estimation of area under the curve (AUC). An optimal cut-off was
also proposed by identifying a point that would give maximum sensitivity
with an estimated specificity of 1.0. A specificity of 1.0 was selected (i.e. no
false positives within the study data), to minimise the possibility that a
potential survivor would be subjected to euthanasia inappropriately.
Estimated sensitivity was reported together with estimated 95% confidence
intervals for sensitivity based on 2000 bootstrap replications of receiver
operating characteristic curves.
As a potential clinical discussion tool the percentage weight changes for
horses over each interval and period were summarised to estimate the
probability of survival of horses grouped into ranges of percentage weight
change (percentage survival prediction curves). As these estimates were
based on low numbers of individual horses the uncertainty in the estimates
was expressed with binomial exact confidence intervals.
As bodyweights were only recorded during the hospitalisation period
and few horses were admitted on the day of onset of clinical signs, weight
data were generally not available from the day of disease onset. To
determine if correcting for this delay would improve predictive
performance, extrapolations were performed to estimate the weight on
the day of disease onset, i.e. the first day that owners recognised
abnormal clinical signs. The extrapolation to day of onset used a quadratic
model fitted to each horse’s first 6 recorded weights, only when a weight
was available ≤7 days after the onset of clinical signs, and where ≥6
weights had been recorded. These inclusion criteria for extrapolation were
selected on iterative examination of fitted values under different criteria
and discussion with experienced clinicians blind to the outcome of the
individual horse. An extrapolated onset weight was not calculated for
horses outside these criteria. Histograms and the associated quantitative
data were produced for both extrapolated data (Day 0 = day of disease
onset) and nonextrapolated data (Day 0 = day of first recorded weight) for
all time intervals.
The R statistical systemb was used for all statistical analyses. P<0.05 was
used as the threshold for statistical significance. This study conformed to
Standards for the Reporting of Diagnostic Accuracy guidelines where
appropriate.
Results
Since 28 of the 241 horses hospitalised for management of chronic grass
sickness met the case exclusion criteria, the study sample comprised 213
horses. Median age was 5 years (IQR 3.5–8). There were 96 (45.1%)
females, 104 (48.8%) geldings and 13 (6.1%) entire males. Breed categories
consisted of 22 (10.3%) Scottish native ponies, 31 (14.6%) other ponies, 19
(8.9%) Thoroughbreds, 42 (19.7%) cobs, 17 (8%) draught horses, 11 (5.2%)
Warmbloods, 13 (6.1%) other pure breeds and 58 (27.2%) crossbreeds. No
case background variables were associated with increased risk of
nonsurvival.
There were 114 (53.5%) survivors and 99 (46.5%) nonsurvivors. The
survival rate was (53.5%) for the 213 horses included in the study, and
49.4% for all (241) horses hospitalised for management of chronic grass
sickness during the study period. All nonsurvivors were subjected to
euthanasia, with none dying. For 92 of the 99 nonsurvivors, information
was available describing the indications of euthanasia. The most prevalent
(29.3% of nonsurvivors) single indication for euthanasia was recumbency
and inability to stand. Seven cases were subjected to euthanasia for other
single indications including aspiration pneumonia, functional post renal
obstruction, cardiovascular collapse, diarrhoea, persistent anorexia and
recurrent colic. Fifty-eight horses (63%) were subjected to euthanasia for
multiple indications (Supplementary Item 1). Although weight loss (28 of
58, 48.3%) was the most prevalent indication when multiple indications for
euthanasia were present, horses were never subjected to euthanasia solely
because of weight loss.
There was no significant difference in age of survivors (median 5 years,
IQR 3–8) and nonsurvivors (5 years, IQR 4–8), nor in duration of disease
prior to hospitalisation (survivors 6 days, IQR 2–10; nonsurvivors 5 days,
IQR 2–8). Survivors were hospitalised for significantly longer than
nonsurvivors (survivors 34 days, IQR 22–60; nonsurvivors 14, IQR 10–25;
P<0.00001; Fig 1). Kaplan–Meier survival curve indicated that 50% of
nonsurvivors were subjected to euthanasia by 21 days and 75% by 32 days
from onset of disease (Fig 1a). A time to discharge curve for survivors
indicates that 50% were discharged by Day 42 from onset of disease
(Fig 1b).
Horses were weighed on average every 2 days (IQR 1–3); the frequency
was not significantly different between survivors and nonsurvivors.
Compared with nonsurvivors, survivors had significantly lower maximum
bodyweight loss as percentage of first weight (survivors 5.9%, IQR 1.8–13.5;
nonsurvivors 12.7, IQR 6.4–17.3; P<0.0001), and a significantly earlier day
of minimum weight (survivors Day 17, IQR 13–27; nonsurvivors Day 23, IQR
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Fig 1: a) Kaplan–Meier survival curve for 99 nonsurvivors, and b) curve
describing the duration of hospitalisation for 114 survivors.
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survivors gained weight or shortly reached their nadir and then rapidly
increased, making the overall gradient of the curve less in survivors (Fig 2).
The highest percent of total bodyweight loss by individual survivors and
nonsurvivors was similar (36% and 37%, respectively).
Using overall magnitude and rapidity of bodyweight change data
referenced to first weight, survivors had significantly lower weight loss than
nonsurvivors at all periods listed in Table 1. The greatest percentage of
bodyweight loss within a 7 day period occurred between 0 and 7 days, for
both survivors and nonsurvivors. The AUC was similar for all time periods,
but highest between 14 and 21 days. When the cut-off was set to give a
specificity of 1.0, sensitivity was fairly low for all time periods, but was
greatest for the 7–14 day interval (Table 1).
The percentage bodyweight change of survivors and nonsurvivors from
Day 0 (first weight) to 7 is presented in Fig 3, with histograms for other
time intervals being presented in Supplementary Item 2. Percentage
survival prediction curves are shown in Fig 4.
All the aforementioned results reported and later discussed are based
on nonextrapolated data, with Day 0 as the first weight recorded. Only 93
horses met the criteria for extrapolation to estimate a weight at onset of
disease. The predictive performance measures based on extrapolated
weights were overall less informative than the measures based on first
weight recorded (AUC lower for 7/8 models based on extrapolated weight
compared with first weight). As extrapolation only estimates the weight at
onset, it is possible that the standardising of timing it adds is overwhelmed
by the error introduced by the quadratic model extrapolation.
Discussion
This is the largest study to report the outcome of chronic grass sickness
cases [1–4]. The survival rates of 49.4% for all (241) horses hospitalised for
management of chronic grass sickness during the study period, and of
53.5% for the 213 horses included in the study, were higher than previously
reported (35.6% [1] and 42.7% [2]). The difference in percentage survival of
all 241 horses compared with the 213 horses used in the study reflects the
higher number of nonsurvivors in the excluded sample (23/28), probably
because some were subjected to euthanasia soon after admission, prior to
recording the ≥2 weights required for study inclusion.
For any given change in percentage bodyweight over any of the defined
time intervals the percentage survival prediction curves report the survival
rate in our study sample gathered over the last 16 years. These curves can
be used to predict the survival of future cases. Obviously each clinical case
should be assessed on a case by case basis – for example if the horse has
concurrent aspiration pneumonia or colic, or is one of the outliers – but
these values can be used as a prognostic discussion aid derived from
previous outcomes, to help guide owner decisions. For example, if a horse
had lost 5% bodyweight after 21 days and the owner was considering
euthanasia, our data indicate that 100% of horses losing this amount of
weight over this time period previously survived to discharge.
Compared with nonsurvivors, survivors had significantly lower median
maximum bodyweight loss overall and for each individual time period
analysed. The greatest difference in median weight loss of survivors and
nonsurvivors occurred between Days 14 and 21. The greatest AUC was
also for this time period; however, the confidence intervals of all areas
overlap, so we cannot report that this value is significantly greater. Whilst
the AUC is an objective measure of overall discrimination, both this and the
difference between the medians is a population statistic and is not
indicative of the best diagnostic predictor for discriminating survivors from
nonsurvivors on an individual basis. With a guaranteed specificity of 1.0,
the highest achievable sensitivity was 0.22 for the 7–14 day time interval.
However, the value 0.22 is not significantly greater than other intervals due
to the low sample sizes in each group. In conclusion, we were unable
definitively to select a single 7-day interval of time over another as the best
discriminator between survivors and nonsurvivors. As weight loss data
from longer intervals (0–14, 0–21 etc.) did not provide more predictive
data than from 7-day periods, the latter are preferred because they are
easier to obtain practically.
Data from the Kaplan–Meier survival curve aided the selection of periods
of time to analyse the changes in bodyweight. Since only 29.3% of
nonsurvivors survived beyond 28 days, data for subsequent time periods
(>28 days) were less predictive. Furthermore, factors other than weight
loss appeared to contribute to nonsurvival in horses beyond 28 days,
explaining the outlying cases for nonsurvivors evident in Figure 2. For
example the horse subjected to euthanasia after 4 months had reached its
nadir and started to increase weight but was subsequently subjected to































Fig 2: The temporal courses of individual horse’s bodyweight as a percentage of the first recorded weight, for nonsurvivors and survivors.
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The median maximum percentage weight loss for survivors from first
weighing was similar to that previously reported (5.2% for 34 horses;
[2]). Clearly these data underestimate the actual weight loss occurring
from disease onset. We would have hypothesised that horses lose the
greatest percentage of bodyweight within the first week because of the
initial reduction in mass of gastrointestinal contents. The greatest
percentage total bodyweight loss for individual horses was comparable
for survivors and nonsurvivors, demonstrating that survivors can survive
despite losing significant weight. This emphasises our recommendation
that horses should not be subjected to euthanasia solely on the basis
of weight loss.
The median age of all horses in this study is consistent with previous
reports regarding equine grass sickness [9,10]. Unlike Milne et al. [1] who
found ponies significantly less likely to survive than cobs and Doxey et al.
[3] who found cobs and Thoroughbreds overrepresented in survivors, no
breeds in the present study were associated with an increased risk of
nonsurvival.
The duration of hospitalisation for survivors (34 days) was comparable
for horses treated between 1991 and 1994 (median 31 days) [2]. Horses
were typically discharged from the hospital when they were consistently
gaining weight while receiving feeds at a frequency that the owners could
continue to feed at home. Obviously this is dependent on owners’
willingness or desire to have the case home before recovery is fully
established. Few cases had returned back to their original weight at the
time of discharge. Doxey et al. [4] did not find any correlation between
duration of hospitalisation and subsequent quality of life of horses.
It is important to note that horses were never subjected to euthanasia
solely because of weight loss. The most prevalent single reason for
euthanasia was recumbency and inability to stand due to skeletal muscle
weakness. The pathogenesis of muscle weakness in chronic grass sickness
is unclear, but is likely to reflect muscle catabolism subsequent to cachexia
and possibly neurogenic motor weakness [11]. It is unsurprising that
weight loss was reported as the most prevalent indication when multiple
indications for euthanasia were reported.
Currently, the diagnosis of grass sickness can only be definitively
confirmed by histopathology of autonomic ganglia at post mortem or
biopsies of the enteric nervous system collected at exploratory laparotomy
[12,13]. In the present study chronic grass sickness was presumptively
diagnosed after considering the nature and progression of clinical signs,
history, case background, epidemiological factors and elimination of
alternative diagnoses [7]. Diagnosing chronic grass sickness by clinical
examination, by clinicians familiar with the disease, has a reported
accuracy of 100% [3]. Consistent with these data, all 79 nonsurvivors that
had a post mortem examination including histopathological examination of
neural tissue were confirmed to have chronic grass sickness. Consequently
we consider that diagnostic errors were unlikely to have influenced the
conclusions of this study.
Survival was defined as discharge from the hospital. While long-term
follow-up of cases was not done, previous studies indicate that the
majority of chronic grass sickness horses return to full athletic function
[2–4]. Doxey et al. [2] reported that 4 of 35 chronic grass sickness cases
were subjected to euthanasia or died subsequent to hospital discharge.
The pathogenesis of weight loss in equine grass sickness is
incompletely understood but is likely to be multifactorial, reflecting
some of the following; lack of food intake; increased metabolic rate;
cachexia and neurogenic muscle atrophy. The authors are unaware of
studies reporting the magnitude of weight loss sustained in horses
following simple starvation, which could have been used to determine
if weight loss is largely a consequence of reduced feed intake or if
cachexia is a contributing factor. Horses experimentally deprived of
food and water for 7 days had a 10% (range 8.2–10.3%) median body
weight loss [14]. In the present study, 23% of horses lost ≥10%
bodyweight over the first 7 days from the first recorded weight,
suggesting that mechanisms other than simple starvation, such as
cachexia, contributed to weight loss. Furthermore, since chronic grass
sickness cases were drinking and not completely anorexic, the weight
loss would be expected to be less than reported with complete food
TABLE 1: Median percentage bodyweight changes for various time intervals for survivors (S) and nonsurvivors (NS) from the first recorded
weight, with associated areas under the receiver operating characteristic curve (AUC) and highest achievable sensitivity, when specificity
was set at 1.0
Time
interval
(days) S, (%) median (IQR) NS, (%) median (IQR)
Difference between the medians of S







0–7 -3.4 (-6.4 to -1.1) -7.2 (-9.6 to -5.5) 3.80 0.82 0.76–0.88 0.21 0.12–0.32
7–14 -1.8 (-4.9 to 0.2) -5.9 (-7.4 to -4.7) 4.10 0.84 0.77–0.91 0.22 0.10–0.37
14–21 -0.02 (-2.6 to 0.9) -5.4 (-6.6 to -5.0) 5.38 0.91 0.84–0.98 0.09 0.00–0.77
21–28 -0.2 (-2.3 to 1.7) -5.0 (-5.5 to -2.8) 4.80 0.85 0.76–0.95 0.08 0.00–0.25
0–7 -3.4 (-6.4 to -1.1) -7.2 (-9.6 to -5.5) 3.80 0.82 0.76–0.88 0.21 0.12–0.32
0–14 -6.1 (-10.3 to -0.9) -12.3 (-15.1 to -10.1) 6.20 0.83 0.76–0.90 0.20 0.10–0.37
0–21 -7.5 (-12.9 to -2.8) -16.6 (-18.7 to -15.1) 9.10 0.88 0.81–0.95 0.18 0.05–0.36
0–28 -9.2 (-15.5 to -2.2) -19.9 (-22.8 to -18.1) 10.70 0.87 0.78–0.96 0.25 0.08–0.50



















Fig 3: Histogram demonstrating the percentage bodyweight change of survivors
and nonsurvivors from Day 0 (first weight) to Day 7. For example 13 horses lost
2% bodyweight and all these were survivors. Six horses lost 12% bodyweight and
all were nonsurvivors. Thirty-one horses lost 6% bodyweight and these horses
were a mixture of survivors and nonsurvivors.
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and water deprivation. Cachexia is distinct from simple starvation,
being defined as a complex metabolic syndrome associated with
underlying disease and characterised by loss of muscle [15]. Consistent
with involvement of cachexia in grass sickness, affected horses have
amino acid perturbations that resemble severe protein malnutrition,
consistent with cachexia, and differing from simple starvation [16].
Weight loss is a powerful independent variable that predicts mortality
in human patients with cancer [17] or human immunodeficiency virus
[18], and the elderly in nursing homes [19]. Excessive elaboration of
proinflammatory cytokines such as interleukins 1 and 6 and tumour
necrosis factor a is reported as the most common cause of cachexia
in acutely ill human patients [20]. Proinflammatory cytokines signal an
increase in the synthesis of acute phase proteins by hepatocytes.
Increases in acute phase proteins such as fibrinogen, serum amyloid A
[21] and haptoglobin [22] have been reported in equine grass sickness,
suggesting activation of the entire inflammatory cascade and may
provide further evidence that chronic grass sickness horses are
cachectic.
Potential errors in the data for duration of disease upon hospital
admission, obtained from owners, may have resulted from delayed
recognition of the subtle early signs of chronic grass sickness particularly in
horses at pasture. Greater sample sizes within the individual time intervals
would be required for greater sensitivity and associated confidence
intervals. Despite a relatively high prevalence of the disease in this area
[6,23], a significant extension in the time period for which the data were
collected would be required for greater sample sizes. The percentage
survival prediction curves could be used prospectively to determine their
accuracy. The percentage survival prediction curves are applicable to our
study population, and are likely to be less applicable to horses, that do not
receive intensive nursing care.
The recorded bodyweights in the study were obtained with an accurate
weighbridge. To allow practitioners and owners in an ambulatory setting to
use the percentage survival predictive curves, we performed a pilot study
to determine which weigh tape measurement method would most
accurately estimate the bodyweight (Supplementary Item 3).
In conclusion, nonsurvivors had greater bodyweight loss than survivors.
Rapidity and magnitude of bodyweight loss were equally predictive of
outcome. Percentage survival prediction curves provide objective data to
aid discussion of prognosis, but greater predictive specificity with
associated sensitivity is required for clinical decision making for individual
horses.
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